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For the first time since the 
1960s, life expectancy declined 
in the U.S. two years in a row. 
Remarkable given the absence 
of a major war, this corre-
sponds with increases in death-
by-overdose among young men 
and women. While many hoped 
that the 21st century would 
witness significant reductions 
to dependent relationships 
with various substances and 
activities, the problem has 
endured and even proliferated.
The current crisis is relevant 
to every one of us. Not just 
because few people go unaf-
fected by the epidemic—those 
lucky enough not to have lost 
friends or kin to addiction 
almost certainly know others 
who have—but also owing to 
the way in which its intensifica-
tion involved and continues to 
affect the medical community.
It’s complicated, of course. 
If solving the crisis was only a 
matter of tactical shifts, such as 
different attitudes toward the 
treatment of physical pain, doc-
tors could adjust their behavior 
and expect to see significant 
progress in ending the epidemic. 
A quick glance at the history of 
humankind’s relationship with 
drugs, however, confirms the 
lament that there is “no new 
thing under the sun”: crises like 
these have occurred before, and 
successfully resolving them 
has required more than swift, 
decisive action, though that is 
needed too. 
Some successful efforts to 
combat the crisis have begun 
here at Yale. Pioneered by 
students, faculty, and alumni, 
our community has conceived 
of, tested, and implemented 
programs and techniques that 
show great promise in helping 
to halt the epidemic. It’s inspir-
ing to be able to share stories 
of how the school’s faculty and 
alumni apply their expertise 
to such a pressing social need. 
Their innovations will certainly 
have an impact on the struggle 
to gain control over the deluge 
of overdoses.
Shelter from the Storm is 
my first issue as editor of Yale 
Medicine Magazine, and I can’t 
think of a more pressing topical 
theme than this to cover. Every 
one of us can help shape solu-
tions by thinking more carefully 
about the way we talk and think 
about drugs and those whose 
lives are affected thereby. We 
can be more careful with the 
words we choose, the choices 
we make in describing serious 
health challenges. Ultimately, 
we’re all in this together, and 
beating the opioid epidemic is 
going to take all of us, working 
in concert to check the rising 
tide of this public health crisis.
Adrian Bonenberger  
Editor, Yale Medicine Magazine
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letter from the editor
  Balancing patient pain with ethical  
treatment: a doctor’s dilemma
the medic a l profession has gone back and forth in its approach 
to pain treatment. Alcohol and opioids, once seen as miraculous and 
valid ways to assuage pain from injury or chronic disability, are now 
viewed—and used—differently. Dean Robert J. Alpern, M.D., discusses 
what has changed since he was trained as a physician—and what that 
bodes for the future.
Has the landscape changed in terms of how the medical community discusses individuals  
with substance use disorder challenges? Many years ago the treatment of pain was 
dominated by the traditional philosophy of “do no harm.”  We as physicians under-
treated pain due to the fear of causing addiction and overdoses. Then there was a 
period when medical professionals saw undertreatment of pain as a kind of harm, 
and we went through a period of increasingly aggressive pain treatment, which led 
to the development and expansion of pain as a specialty. Medical schools and health 
systems began developing and expanding pain programs, because as it turns out, it’s 
very difficult to treat pain effectively. 
Most recently, we’ve seen that pain treatment that frequently relies on opioids has 
secondary and even tertiary consequences, causing an epidemic of addiction and 
overdoses. Now the medical profession is pulling back, trying to find the right balance.
Do you feel that part of the issue with substance use disorder surrounding pain medication 
involves the idea that one should not have to feel any pain? No, I don’t think so. Medically, 
you were always balancing the patient’s comfort with risk to the patient’s health. The 
ideal would be to treat pain in ways that don’t involve opiates. Steve Waxman’s research 
into blocking specific sodium channels that affect the sensation of pain is extremely 
promising. But there’s a danger, too. If you block all pain sensation, a patient could burn 
themselves and not know it. There’s a reason we feel pain. 
What’s the School of Medicine’s role in the substance use disorder epidemic? Yale is very 
strong in substance use disorder research. Our faculty in psychiatry, general internal 
medicine, and emergency medicine are world-class experts on the subject. Substance 
use disorder spans many variables so, while many of them work in opioid addiction, 
others focus on tobacco, alcohol, food, and other things. In every case, Yale should be 
among the first to take the most effective practices to the bedside. I hope that in the 
near future, someone suffering pain will be able to receive treatment specific to their 
ailment that isn’t addictive.
dialogue
»
   Patient navigators 
address barriers to health care
priscilla wang, m.d. ’17, recalled a frightening moment 
at her patient’s house. She watched in dismay as the man, 
who had disabilities, clung for balance to flimsy towel bars 
in his bathroom.
 
“It made me really upset. … He 
could easily fall; he could break 
his hip because of this unsafe 
arrangement,” Wang said. Yet his 
health insurance did not make 
funds available to help prevent 
a potentially catastrophic and 
expensive injury. 
“This experience was really 
eye-opening, in that it made me 
realize that it’s in the day-to-day 
settings that health is deter-
mined,” she said.
The home visit took place as 
part of a pilot patient navigators 
program Wang co-founded in 
2016. The Yale Patient Navigator 
Program (PNP), pairs nine teams 
of senior and junior medical stu-
dents with patients from Yale’s 
primary care clinics who face 
serious social barriers to health. 
Supported by lectures from fac-
ulty, social workers, and New 
Haven outreach workers, and 
through visits with patients, the 
students learned to go beyond 
brief clinical encounters in 
order to listen to and learn what 
patients are up against, and pro-
vide meaningful support.
“Many of the problems we 
address in the hospital are not 
necessarily biological in their 
root causes. There are many 
ways in which medical students 
can meaningfully address these 
deeper issues,” said Wang, who 
worked on the project before her 
graduation last May.
Indeed, the quest for better 
health asks a lot of patients—lit-
eracy, transportation, disposable 
income. Being unable to read, 
travel to the doctor’s office, or 
pay for parking can derail even 
the best medical advice. Many 
people risk being fired if they 
miss work for a doctor’s appoint-
ment. Others contend with 
domestic abuse or the criminal 
justice system. Cars break down, 
buses don’t serve the neighbor-
hood or don’t arrive, and missed 
appointments ensue, which 
can lead providers to discharge 
patients from the clinic. People 
may lack information about 
healthful living or support for 
quitting tobacco, or are confused 
by their doctors’ instructions. 
Some people simply mistrust the 
health care system. Such prob-
lems don’t get much space in for-
mal med school curricula.
So the student navigators 
helped their patients make sense 
of multiple bottles of medicine. 
They connected people to food 
assistance, discounted transpor-
tation, and low-income housing. 
One man lacked a phone, so his 
student team signed him up for 
a free Obama Phone (cell phones 
for low-income Americans). 
Nisha Dalvie, then in her first 
year of medical school, accom-
panied her patient, a man in 
his 50s, to the courthouse for 
help with housing; to his physi-
cal therapy; and to the housing 
authority. Not only did he con-
tend with diabetes and a condi-
tion causing muscular weakness, 
but he also had low literacy. He 
had trouble reading forms and 
medication instructions, but he 
didn’t want to attend a nearby 
literacy program and reveal his 
difficulty to people he’d known 
since childhood. Dalvie and her 
teammate, fourth-year medi-
cal student Sean Maroongroge, 
helped him obtain tutoring in 
another part of town where he 
could study in anonymity. 
ymm.yale.edu4
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Co-founded by Wang, 
Sewanan, Eamon Duffy, 
Julianna Berk-Krauss, and 
Matt Meizlish, and supported 
by several physician advisors, 
including Pinar Oray-Schrom, 
M.D., HS ’02, assistant profes-
sor of medicine (general  
medicine), the program com-
pleted its pilot year to rave 
reviews from students who 
participated. One student 
called it “one of the most  
formative experiences of my 
Yale career.” Another wrote, 
“There is nothing at Yale more 
patient-centered than this.”
Patient navigation has its 
roots in a program started by 
Harold P. Freeman, M.D., in 
Harlem in 1990 to assist primar-
ily the poor and uninsured to 
access cancer care; it grew to 
become the Harold P. Freeman 
Patient Navigation Institute, 
which now trains navigators all 
over the country. New Haven’s 
Gateway Community College 
also offers training. 
Sewanan said the student 
program was also inspired by 
“hotspotting,” an approach pio-
neered by Jeffrey Brenner, M.D., 
in Camden, N.J., in which teams 
of providers work directly with 
high-risk patients who use the 
most health care services. The 
teams address social needs as 
well as smoothing paths through 
the health care system, with a 
resulting drop in the need for 
hospital services.
For Wang, learning more 
about her patient’s life was such 
a powerful experience that she 
switched career plans while on 
the residency interview trail. 
First-year medical 
student Nisha Dalvie 
joined hoping to help 
patients navigate the 
health care system. 
Volunteering with 
the Patient Navigator 
Program offered a way 
to help the community 
while also broadening 
her understanding of 
what types of chal-
lenges patients face.
“It was great to see how many 
things were available for him by 
basically just googling things and 
emailing people, trying to figure 
out what we could do,” Dalvie 
said. “There’s so much out there, 
and you really don’t learn it in 
medical school.”
The PNP is an outgrowth of 
Students for a Better Healthcare 
System, which M.D./Ph.D. stu-
dent Lorenzo Sewanan and sev-
eral other students founded in 
2012 to help educate New Haven 
residents about the Affordable 
Care Act. During teach-ins they 
conducted in schools, churches, 
and at the School of Medicine, 
the students picked up on prob-
lems that go beyond health 
insurance. “Even though more 
and more people were having 
‘access’ to health care or at least 
health care insurance,” Sewanan 
said, specifying the quotation 
marks, “it didn’t necessar-
ily mean they were getting to 
receive the best care or getting 
the benefits of that care.” 
The difficult world some 
patients inhabit was uncharted 
territory for students like 
Dalvie, who said she had a 
privileged upbringing. 
“There’s a lot of tension in this 
city, I feel, between people who 
are impoverished and the stu-
dents, who are most often not,” 
Dalvie said. “I hadn’t really seen 
it like that in any other place 
where I’d been, where those who 
didn’t have as much were so in 
the forefront of the city. … We 
got to see how all of these issues 




















Last November, Yale 
School of Medicine 
doctors, PhDs, law-
yers, activists, and 
recovering addicts 
gathered to brain-
storm solutions to the 
epidemic of opioid use.
For more on story,  
visit ymm.yale.edu/opioid
and Dental Education Program 
(SMDEP). Yale, along with other 
schools, had offered the program, 
funded by the Robert Wood 
Johnson Foundation, since 1997 
to help college students from dis-
advantaged backgrounds learn 
how to navigate the med school 
application process and teach 
them basic science knowledge 
and communications skills.
In 2013, Hutchins was one 
of 80 students from around the 
country who came to Yale for the 
six-week residential program. 
He arrived with some trepida-
tion. Ivy Leaguers, he was sure, 
would be rich stuck-up snobs. “I 
had all those preconceptions,” he 
said. Instead, he found an accept-
ing and welcoming environment 
filled with “regular people who 
just happened to be at Yale.”
At summer’s end, he returned 
to Toledo with not just new skills 
but also a new dream. He would 
study at an Ivy League school.
“Everybody told me I was 
crazy,” Hutchins said. “All I kept 
hearing was, ‘You can’t do that.’ ”
He graduated from Bowling 
Green State University in 2016 
and that fall matriculated at the 
School of Public Health, where 
he’s on track to graduate with 
a degree in health manage-
ment in May 2018. This year, he’s 
second in the program and he’s 
the 2017 Cornell Scott Scholar, 
an honor awarded each year by 
Wang abandoned her plans to 
train in categorical internal 
medicine, instead landing a 
last-minute spot in the primary 
care residency at Harvard’s 
Brigham and Women’s Hospital 
in Boston—a change of heart for 
someone who began medical 
school interested in orthopae-
dic surgery.
“It’s a really humbling, a 
really powerful experience to 
step into a patient’s home and 
see the challenges that they  
live with on a day-to-day basis,” 
she said.
This year, navigators are 
expanding their reach to 
include patients with diabe-
tes and mental health issues. 
They’re also adding students 
from other fields, including 
nursing students and social 
work students from Southern 
Connecticut State University.
With the Affordable Care 
Act and social services under 
threat in the current political 
climate, patients and physi-
cians face ever-stiffer head-
winds. Still, Sewanan believes 
that patients and medical 
students possess the power to 
make an impact. “If we can’t 
achieve what we want at the 
policy level,” Sewanan said, “I 
think there’s still a lot that can 
be done at the personal, indi-
vidual level.” 
— Jenny Blair, M.D. ’04
»
YSM offers a leg up  
to students aspiring to 
medical careers
At the age of 42, Shermaine 
Hutchins has more life experi-
ences under his belt than many 
of his classmates at the School of 
Public Health. He was raised in 
Daytona Beach, Florida, by a single 
mother who provided for him 
and his younger brother with her 
wages as an aide in a retirement 
home. He graduated from high 
school in 1993, unsure of his path 
in life, and climbed up the ladder 
at McDonald’s from “fries to man-
ager.” In 1998, he joined the Army, 
trained as a medic, and served 
on a humanitarian mission in 
Nicaragua, where he cared for his 
fellow troops and local villagers. 
He mustered out in 2002, still 
not knowing where life would 
take him. A chance encounter in 
a mall led to a job as a DJ at a radio 
station that played rhythm and 
blues and hip-hop. Again, he rose 
up the ladder, continuing as an 
on-air personality while taking on 
behind-the-scenes roles in man-
agement and production. His career 
took him to Ohio, where he saw the 
writing on the wall for “terrestrial” 
radio. Spotify, MP3 players, and 
streaming services were chang-
ing how people listen to music 
and challenging radio’s business 
model. In search of a more secure 
livelihood, Hutchins thought back 
to his time as a medic and decided 
to become a nurse. He began tak-
ing pre-med courses at Owens 
Community College in Toledo.
Then, two things happened. 
He decided he’d rather be in 
health care management than in 
clinical care. And he was accepted 
into Yale’s Summer Medical 
ymm.yale.edu6
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could be whatever I want to be,” 
Williams said.
“It was overwhelming,” added 
Ama Dondorful-Amos, who 
took the course last summer 
with Williams. Dondorful-Amos 
arrived in the United States from 
Ghana two years ago, and hopes to 
become a pediatrician. “It opened 
up new perspectives. I learned how 
to run gels, how DNA replicates.”
For Beth Schmidt, the course 
sent a message that at 51, she 
too can aspire to medical school. 
Medicine has been part of her 
life since childhood. Both her 
parents were medical corpsmen 
in the U.S. Navy. She studied 
art history in college but spent a 
career as a marketer for medical 
device companies. Although she 
longed to study medicine, she 
felt she couldn’t afford medical 
school. After the YSEMA course 
ended, she secured an intern-
ship at a lab at the medical school, 
which became a paid position 
in January. She couldn’t have 
done it, she said, without a class 
called Introduction to Research, 
taught by Hutchins. “He was very 
encouraging,” she said.
Such responses are gratifying 
to Hutchins, who is determined 
to use his story as an example to 
others. Last summer, although he 
had an internship with the CFO 
of Partners HealthCare in Boston, 
he returned to New Haven twice 
a week to teach the research class. 
But he also offered pep talks in 
what is possible in life: such as 
attending an Ivy League school.
“I remember that feeling that 
no one is in your corner and no 
one believes that you can do 
it,” he said. “I wanted to be that 
voice that told them that they 
could do it.”
—John Curtis
“We really have identified the 
population that the School of 
Medicine is seeking to develop 
and nurture—first-generation 
students, DACA students, stu-
dents who are underrepresented 
in medicine,” she said. Too often, 
she added, these are students 
who, “when they say they want 
to be a doctor, hear ‘You can be 
an aide.’ ”
The program includes organic 
chemistry, biology, writing and 
communications, introduction to 
research, and mentoring workshops.
“Clearly, it tells them what they 
are in for down the road,” said 
Antonios Pappantoniou, Ph.D., a 
professor of biology at Housatonic 
Community College. “Students 
often don’t have an impression 
of how much work it takes to get 
into medical school. This gives 
them some training in advance.”
An integral feature of the 
course is meeting Yale students 
like Hutchins, who shares the 
experiences of many of the 
students. Last year’s inaugural 
YSEMA class included Felicia 
Williams, a 45-year-old pro-
gram manager for Goodwill. She 
already has a bachelor’s degree 
from Albertus Magnus College 
in social science, but came 
to Gateway to make a career 
change. She’d like to become a 
pharmacist. She found the pro-
gram challenging but encourag-
ing. “It makes me know that I 
the Community Foundation 
for Greater New Haven to a Yale 
public health student who dem-
onstrates a commitment to com-
munity-based health care.
“I wouldn’t be here without 
SMDEP,” Hutchins said. But the 
program is no longer available at 
Yale. Because Yale has no dental 
school, it had to withdraw from 
the national program in 2016.
When word came that Yale 
could no longer participate in 
SMDEP, Linda Jackson, direc-
tor of diversity, inclusion, com-
munity engagement, and equity 
at the medical school, and Darin 
Latimore, M.D., deputy dean for 
diversity and inclusion, decided 
to launch a program that would 
serve local community college 
students. Jackson reached out to 
officials at Gateway Community 
College in New Haven and 
Housatonic Community College 
in Bridgeport. Last summer, 
19 students attended the inau-
gural Yale Summer Enrichment 
Medical Academy (YSEMA), a free 
six-week program for students 
interested in careers in medicine.
At an informational meeting 
at Gateway in November, Jackson 
told about 30 prospective stu-
dents what to expect from this 
year’s course, which will accept 
up to 25 students.
“If you’re interested in being 
a physician, physician assistant, 
or nurse, this will help you on 
that road,” said Jackson, herself a 
graduate of Gateway. “We are get-
ting you ready for the next step. It 
is a very rigorous program. You 
will learn a lot.”
Also at that session at Gateway 
was Lauren Doninger, Ph.D., a 
professor of psychology who 




2017 was a bad year 
for natural disasters. 
Hurricanes, floods, 
and fire hit com-
munities across the 
U.S. Yale School of 
Medicine alumni lived 
and worked in many of 
them, and took part in 
leading relief efforts.
For more on story,  
visit ymm.yale.edu/relief
»
The DNA repair–breast 
cancer connection
The gene known as BRCA1 (for 
“breast cancer susceptibility 
gene 1”) has a storied history. It 
was the first gene identified as 
contributing to familial breast 
cancer risk, and its discovery in 
1990 led scientists and doctors 
to accept the theory that breast 
cancer could be inherited. Now 
experts know that having a muta-
tion that inactivates the breast 
cancer gene increases a woman’s 
chances of getting breast cancer 
about sixfold. 
While scientists know much 
about how dysfunctional BRCA1 
protein leads to cancer, they 
know little about what the pro-
tein actually does in cells. In a 
paper published in Nature this 
fall, Patrick Sung, D.Phil., pro-
fessor of molecular biophysics 
and biochemistry and of thera-
peutic radiology, reports findings 
that shed light on the function of 
the breast cancer protein in the 
repair of broken DNA. 
Sung has been studying the 
homologous recombination 
method of DNA repair for more 
than 20 years. This DNA repair 
mechanism takes place when 
the cell is about to divide, after it 
has duplicated its chromosomes —
bundles of double-stranded 
DNA—but before each chromo-
some and its duplicate have 
split off into separate cells. In 
homologous recombination, a 
large number of proteins func-
tion together to repair a DNA 
break in one chromosome by 
copying the broken section from 
the duplicate chromosome to 
patch up the break. First, for a 
short distance on either side 
of the break, one strand of the 
DNA is shaved away to form a 
single-stranded end. Next, each 
single-stranded end inserts 
itself between the two strands 
of the duplicate chromosome in 
order to copy the damaged DNA 
section. Like an interloper at a 
dance, the single-stranded end 
gets between the other chromo-
some’s two strands, pushing 
one of them aside and forming a 
structure called a displacement 
loop or D-loop.
In 1994, working in yeast, 
Sung discovered that a protein 
called RAD51 attaches itself to 
the single-stranded end of the 
broken DNA and leads the inva-
sion of the duplicate chromo-
some. In 1997, another lab 
learned that this invader protein 
physically interacts with the 
breast cancer protein. “We have 
to study this,” Sung thought to 
himself when he heard the news. 
All of a sudden, his research 
became related to breast cancer. 
But yeast, the model system 
Sung had been using, does not 
have the breast cancer protein. 
In order to study the interac-
tions between the invader 
protein and the breast cancer 
protein, Sung had to shift his 
research focus from yeast to 
humans—or, rather, human cells 
and proteins. 
Sung and his team developed 
a method to isolate a significant 
quantity of the BRCA1 protein as 
a complex with a partner protein 
called BARD1. The research-
ers performed experiments to 
test D-loop formation by RAD51 
with and without the breast 
cancer protein and its partner. 
Those tests revealed that the 
duo helps the invader protein to 
form D-loops, and results from 
experiments done in human cells 
confirmed these findings. 
This new information sug-
gests, Sung said, that in breast 
cancer patients with mutations 
in the breast cancer gene, defec-
tive DNA repair likely leads to 
cancer development. In this 
regard, knowledge of how the 
breast cancer protein works 
could aid in drug development.
The findings could also 
empower patients to make 
important choices about their 
treatment. In patients with a 
family history of breast can-
cer, for example, doctors could 
sequence the breast cancer 
gene and the gene encoding its 
partner to look for mutations 
that might impede the pair’s 
functioning. Further, it would 
be possible, Sung said, to recre-
ate a patient’s protein duo in 
the laboratory and test its DNA 
repair abilities to better assess 
the patient’s cancer risk. “Being 
able to apply this type of system 
to look at patient mutations 
will ultimately help patients to 
make decisions, like whether to 
get a mastectomy as a preven-
tive measure,” Sung said. “It’s a 
really big deal. It’s very impor-
tant. Because it’s a huge decision 




It is a sign of enlightenment and 
sophistication for a country to adopt 
democratic methods of govern-
ment. Not so with the brain, it seems! 
According to research conducted by 
a team including Jessica Cardin, Ph.D., 
associate professor in Yale’s Department of Neuroscience, 
the brain takes a more top-down approach. Just 1 percent 
of its neurons are responsible for its development. These 
“VIP” neurons don’t have to worry about gerrymandering 
or primaries—the other neurons obey their prompting 
without question or complaint!
LESS THAN 1 PERCENT OF 
NEURONS ORCHESTRATE 
BRAIN DEVELOPMENT
An exhibit at Yale’s Cushing/Whitney 
Medical Library in October presented 
viewers with an unusual spectacle—the 
first health campaign to create an edu-
cation program using posters designed 
for use by the public. Developed by 
graphic designers and artists working with doctors in the 
Soviet Union in the 1920s, the campaign sought to diminish 
the incidence of syphilis among an overwhelmingly rural and 
uneducated population. While reliable numbers are difficult 
to come by, one assumes that the public health campaign 
made some headway in reducing transmission of the disease. 
In September 2017, a television writer and 
amateur decoder named Nicholas Gibbs 
claimed to have deciphered the Voynich 
manuscript. The Voynich is a unique 
codex that dates from the 15th century 
and resides in Yale’s Beinecke Library. It 
has defied codebreakers for centuries 
and generated a number of curious theo-
ries. Gibbs wrote in the Times Literary 
Supplement that it was “a reference book 
of selected remedies lifted from the stan-
dard treatises of the medieval period, an 
instruction manual for the health and 
well-being of the more well-to-do women 
in society.” Case closed, right? Not so fast, 
Lisa Fagin Davis, Ph.D. ’93, director of the 
Medieval Academy of America, offered 
a swift and authoritative rebuttal of the 
Gibbs theory: “Frankly, I’m a little surprised 
the TLS published it,” she said to Sarah 
Zhang of The Atlantic. And so the enigma 
remains unsolved.
USSR: PUBLIC HEALTH 
PIONEER
TRANSLATION OF WORLD’S  
MOST MYSTERIOUS  
MANUSCRIPT IS UNMADE
For years before his death in 2012 in 
the Galápagos Islands, people around 
the world followed the sad saga of 
“Lonesome George.” The hope was 
that George, the last saddleback 
tortoise of his species, would mate 
before he died. While there wasn’t much anyone could do 
for George, an international expedition from Yale found 
23 tortoises with sufficient DNA to breed a different but 
related saddleback species back into existence. Much will 
depend on the ability of the nine males and 14 females 
to procreate over successive generations. Announced 
in September through the journal Scientific Reports, the 
story may have to wait some time for a happy ending: 
Saddleback tortoises don’t reach sexual maturity for a 
quarter-century. 
YALE RESEARCHERS  


























































































a collection of recent  
scientific findings

ACCO R DIN G TO TH E C ENTER S FO R DI S EAS E CO NTRO L AN D PR EVEN -
TIO N (CDC), approximately 88,000 Americans die each year from what they describe 
as “excessive alcohol use.” Meanwhile, in 2016, the most recent year for which numbers 
are available, drug overdoses accounted for 64,000 deaths—a figure that all indica-
tions suggest will be eclipsed by 2017’s numbers, when they become available. Given 
that alcohol is easily available and socially acceptable, while the drugs that are killing 
men, women, and young people are, hypothetically, difficult to procure, is all the more 
disturbing that the gap between these figures is narrowing so quickly. 
Overdose deaths have become the number one public health crisis in our country. 
This issue of Yale Medicine Magazine explores how courageous faculty, students, and 
alumni from Yale School of Medicine are working to gain control over the storm that is 
raging through our country. From research into new types of pain treatment and pa-
tient care (“How treatment for addiction came out of the Dark Ages,” “Alternatives to 
opioids”) to policy based on clinical experience (“Needed: better strategies for combat-
ing the opioid epidemic”), YSM clinicians and researchers actively seek to reduce and 
destigmatize preventable death from this disease. It’s a daunting task. 
The war over how to describe and treat substance use disorder has tremendously 
high stakes. Yale School of Medicine has produced and continues to produce leaders 
capable of posing ethical, empathetic, system-wide solutions to a deeply subversive  
affliction that, more than ever, holds American citizens in its grip.
 Needed: better strategies for combating the opioid epidemic 12
Alternatives to opioids 18
The road back to good health 22
History of substance abuse 26
 How treatment for addiction came out of the Dark Ages 34


















Improving treatment, exploring solutions 
to the opioid crisis
 Shelter  
from the storm
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For decades, doctors and community 
advocates have worked together to  
combat the epidemic of substance use 
disorder. Lately, that battle has seemed 
harder than ever.
by steve hamm | greg hall illustration
Needed: better strategies for  
combating the opioid epidemic
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Needed: better strategies for combating the opioid epidemic
“Art was the canary in the coal mine,” recalls David 
A. Fiellin, M.D., HS ’95, professor of medicine (gen-
eral medicine), emergency medicine, and of public 
health. Fiellin traveled to Virginia with Richard S. 
Schottenfeld, M.D. ’76, HS ’82, FW ’84, then a professor 
of psychiatry. They learned about the emerging rural 
opioid abuse problem and gave treatment advice to 
about 150 community members, health professionals, 
and counselors gathered in a community center build-
ing near the Kentucky border.
Appalachia was ground zero of an epidemic that 
has since ravaged the nation, with the drug of choice 
shifting from OxyContin to the semi-synthetic opioids 
heroin and fentanyl. “Unfortunately,” says Fiellin, “a 
lot of what Art was concerned about has come true—all 
over the country.” 
More than 60,000 people died of drug overdose, 
mostly from opioids, in the United States in 2016. 
Opioids presently account for more deaths than gun 
homicides and car crashes combined.
“Even though the country has been focused on this 
issue for several years, the problem is getting exponen-
tially worse, not better,” says U.S. Senator Christopher 
Murphy, a Democrat from Connecticut. “The scope of 
the epidemic is absolutely staggering. It’s not young or 
old, black or white, rich or poor. It’s everybody.” Murphy 
is pressing in Congress for increased funding for crisis 
intervention, long-term treatment, and medication 
therapy, and a crackdown on the drug companies and 
physicians who push painkillers that aren’t necessary.
the state turns to yale
Addiction experts at Yale have been at the forefront of 
treatment innovations since the 1970s, so it was no sur-
prise when in 2016 Connecticut Governor Dannel P. Malloy 
asked Fiellin and colleagues at Yale to take the lead in 
designing a strategy to reduce opioid overdose deaths. 
(The death toll in Connecticut reached 723 in 2015, 917 in 
2016, and was projected to exceed 1,000 in 2017.) The result 
was the Connecticut Opioid REsponse (CORE) initiative. 
In October 2016 the initiative issued, in Yale’s Medical 
Historical Library, a report based on input from Yale fac-
ulty, state agencies, hospitals, physicians, nonprofit groups, 
and citizens.
“The solution to the opioid crisis has to be a multi-
pronged approach,” says Fiellin. “We need to decrease 
the availability of all types of opioids, and we need  
to increase the availability of the most effective forms 
of treatment.”
The CORE group recommended six strategies—all of 
which are being acted on by state government leaders. 
The first five were sharply focused—increased access to 
treatment with methadone and buprenorphine; accel-
erated entry into treatment for individuals at high risk 
of overdose; reduction of over-prescription of opioids; 
increased access to naloxone to reverse the effects of 
overdose; and increased sharing of data among state 
agencies, medical clinics, and treatment centers. The 
goal was a more rapid response to overdose outbreaks.
The sixth strategy was more sweeping: to increase 
understanding of the nature of opioid use disorder and 
In 2000, a doctor from tiny St. Paul, Virginia, 
asked the School of Medicine for help with a ter-
rible problem. Art Van Zee, M.D., a physician in 
a community clinic, reported that opioid abuse 
was sweeping Appalachian coal country like a 
tsunami. People he had cared for since infancy 
were overdosing on the prescription painkiller 
OxyContin®. How could this disaster be stopped?
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the most effective ways to deal with it. This strategy is 
critical, according to the Yale team, because much of 
the conventional wisdom about how to deal with opi-
oid use disorder is wrong.
“In essence,” says Gail D’Onofrio, M.S., M.D., professor 
and chair of emergency medicine and a member of the 
CORE team, “the goals are to reduce the stigma associated 
with addiction and understand that it is a chronic, relaps-
ing disease. It has nothing to do with a moral failing, and 
all to do with a remodeling of the brain’s reward system 
that is not easily corrected by short-term approaches such 
as detoxification and enforced abstinence.”
an alternative to rehab
The conventional wisdom, endorsed by some government 
leaders and health care professionals, is that the solution is 
to send people to residential rehabilitation centers where, 
after detoxification, patients are told to abstain completely. 
Not so, says D’Onofrio. She describes this treatment of 
addiction through abstinence as “potentially contributing 
to the worst possible scenario. … When they are released, 
the craving associated with certain cues is still there, but 
now they have less tolerance. The risk of overdose and 
death is very high.”
Research has shown that more than 90 percent of 
those who go through detoxification and attempt absti-
nence will relapse within six months. Opioids rewire 
the brain, causing intense cravings often impossible to 
resist. Rather than detox and abstinence, which do little 
to blunt the craving or undo the remodeling in the brain, 
Yale experts advocate medication-based therapy. The 
long-term use of such opioid agonists as methadone and 
buprenorphine, they say, should not provide a “high” 
but address the underlying cravings and allow people 
to lead productive lives. Treatment with these medica-
tions has been shown to keep people in treatment while 
decreasing cravings, withdrawal, criminal activity, and 
death. Individuals can work, maintain interpersonal 
relationships, and lead productive lives. Methadone 
has, over five decades, proven effective in combating 
heroin addiction. Buprenorphine was approved by the 
U.S. Food and Drug Administration in 2003 after years 
of advocacy by Yale faculty. Unlike methadone, it can 
be prescribed by physicians outside of licensed opioid 
treatment programs.
A study published by Fiellin and colleagues in JAMA: 
The Journal of the American Medical Association 
makes a strong case for long-term use of buprenor-
phine. In a clinical study of people with prescription 
opioid dependence, those in the detoxification group 
who tested positive for illicit opioid use 33 percent 
more often than those in the buprenorphine main-
tenance group. Of the 57 patients in the detoxifica-
tion group, only six stayed in treatment, compared 
to 37 of 56 people in the group that received ongoing 
buprenorphine.
“Treating people with buprenorphine has been one 
of the most meaningful things I’ve done in 40 years as 
a physician,” says Van Zee, the Virginia physician. “It 
can transform people’s lives.”
One of Fiellin’s patients, Jay C., who did not want his 
full name used, can attest to that. He was working as a 
graphic designer 16 years ago when a dentist prescribed 
an opioid painkiller after a tooth extraction. Jay loved the 
euphoria, and soon he couldn’t live without the drug—
partly because he couldn’t face the agony of withdrawal. 
He holed up in his house after he lost his job, and ulti-
mately sold half of his possessions to buy drugs. 
Buprenorphine “saved my life,” he says. Now, at 
age 49, he’s the co-owner of an office cleaning com-
pany, has tapered his daily dose, and plans to get 
off buprenorphine entirely. Still, he’s shaken by his 
experience. “Opioids sink their claws in your soul, 
and they never let go,” he says. 
The Yale substance use disorder experts advocate 
much more widespread use of buprenorphine and nal-
oxone, the overdose antidote. 
screening for care
For years, Yale clinicians have been using naloxone 
in the emergency department for overdose victims. 
Increasingly, police, first responders, and emergency 
medical professionals use naloxone, but advocates want 
to make the drug as prevalent as automatic defibrilla-
tors are in offices, stores, and restaurants. Currently, 
patients who overdose in the Yale New Haven Hospital 
ED are given a take-home dose of naloxone and 
instructions for use. As early as 1999, Yale physicians 
began screening ED patients for opioid and other sub-
stance use disorders as part of a pioneering program, 
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Project ASSERT (Alcohol & Substance Abuse Services, 
Education, and Referral to Treatment). Using a brief 
negotiation interview (formerly known as an interven-
tion) to motivate patients to change their substance 
use, patients are directly linked by Health Promotion 
Advocates employed by Yale New Haven Hospital to 
community partners offering specialized care. The pro-
gram has been very successful over the past 17 years; 
almost two-thirds of all patients with a direct linkage to 
community providers and programs enroll in treatment. 
In 2015 D’Onofrio, Fiellin, and Yale colleagues published 
the results of their study testing negotiation interviews 
for patients with opioid use disorder in JAMA. Patients 
offered a brief negotiation interview and ED-initiated 
treatment with buprenorphine, followed by 10 weeks 
of medical management in primary care led by Fiellin, 
were compared with referral only and brief negotia-
tion interview with a facilitated referral. ED-initiated 
buprenorphine was found to be twice as effective as the 
other negotiation interviews in engaging patients in for-
mal addiction treatment at 30 days, at lower costs.
Buprenorphine and methadone have been found 
effective for up to 80 percent of people with opioid use 
disorder. Because buprenorphine is not as powerful as 
methadone, it carries less risk of an overdose—doctors 
can prescribe the medication after taking an eight-
hour course. 
Prescribing buprenorphine in an office-based prac-
tice—as opposed to methadone in the clinic—allows 
patients to preserve their anonymity if they choose.  
It also helps them avoid running into former opioid-
using associates—chance encounters that might pro-
mote relapse. 
The U.S. Substance Abuse and Mental Health 
Service Administration reports that 968 clinicians in 
Connecticut are certified to prescribe buprenorphine 
as of the end of September 2017, up from 594 at the 
end of 2014. Yet, while the numbers are up signifi-
cantly here and nationally, public health experts say 
some communities remain underserved. “We have 
to increase the number of prescribers,” says Robert 
Heimer, M.Sc. ’80, Ph.D. ’88, professor of epidemiology 
(microbial diseases) and of pharmacology at the School 
of Public Health, and a member of the CORE team.
Needed, he says, are far-reaching education 
programs aimed at physicians. Caregivers in suburban 
and rural areas, where opioids were not a major prob-
lem in the past, must be trained to spot and treat sub-
stance use disorders and reduce their misprescribing of 
opioids, Heimer says. 
Another critical need: increasing the capacity of 
long-term treatment programs and expanding them 
in underserved parts of Connecticut. Too often, people 
who are referred for treatment must wait weeks or even 
months to begin, or travel long distances to clinics.  
As a result, there’s a high potential for continued opi-
oid use with its attendant risks of overdose, arrest, and 
such bloodborne infections as HIV, hepatitis C, endo-
carditis, and soft tissue infections. New Haven’s APT 
Foundation, founded by Yale faculty in 1970 and one 
of the country’s first methadone clinics, has scaled up 
services to help everybody who walks in the door. Its 
open-access model means a person with a drug prob-
lem can walk in without proof of insurance, be evalu-
ated by a clinician, and obtain medication before the 
end of the day. “We have reduced waiting time to zero,” 
says Lynn M. Madden, APT’s chief executive officer. 
The organization serves more than 8,000 patients a 
year in Connecticut.
“We need APT Foundations all over the country,” 
says Schottenfeld, now chair of psychiatry at Howard 
University in Washington, D.C. APT’s open-access 
model, he said, should be applied around the country 
in areas where treatment slots become available only 
when a patient dies or relapses. “That has been the tra-
ditional model, and it doesn’t work.”
a partnership with the state
Expanding services means more resources will be 
needed. Despite Connecticut’s budget crisis (the state 
is facing a deficit of more than $5 billion over the next 
two years), the governor and legislators have commit-
ted to finding money to combat opioid addiction. 
A host of state agencies, including the Department 
of Mental Health & Addiction Services (DMHAS), has 
partnered with Yale faculty on the CORE Initiative. The 
DMHAS is now modifying or amplifying its efforts in 
response to the group’s recommendations. 
Miriam Delphin-Rittmon, Ph.D., FW ’02, the com-
missioner of DMHAS, applauds the CORE team for 
Needed: better strategies for combating the opioid epidemic
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using data to show what works—and what doesn’t. 
“We don’t just implement these things and hope they 
work. We implement them and measure their impacts,” 
says Delphin-Rittmon, who is on leave from the faculty 
of the School of Medicine.
One of the most innovative programs funded 
by DMHAS in partnership with the Connecticut 
Community for Addiction Recovery dispatches “recov-
ery coaches” who help ED patients who seek longer-
term treatment. When necessary, the coaches even 
drive patients to treatment facilities. The program 
recently expanded from four to seven hospitals around 
the state. Still, Connecticut has 27 acute care hospitals, 
so it is available to only a fraction of state residents.
A new program encouraging people to turn in 
unused prescription opioid pills is off to a fast start. 
More than 33,000 pounds of pills were collected last 
year. Also, responding to new state regulations and 
professional guidance, physicians are cutting back on 
opioid prescriptions.
But doctors warn that responses to the opioid epi-
demic must be thought through—lest they adversely 
affect patients. Jane L. Andrews, M.D., assistant pro-
fessor of medicine, says limiting prescriptions puts 
physicians in a bind. “What do I tell my 70-year-old 
patient with arthritis who is getting 30 milligrams of 
OxyContin a day, but still hurts? We need to find new 
alternatives to opioids for long-term pain relief.”
Researchers in Yale’s Department of Psychiatry 
are exploring nonpharmacological methods of deal-
ing with pain—everything from cognitive behavior 
therapy and biofeedback to tai chi and massage. They 
see chronic pain as something to be managed rather 
than “cured,” and they want to place greater respon-
sibility for managing pain on the individual. They’re 
investigating the effectiveness of smartphone apps that 
help people care for themselves. “We’re trying to pro-
mote a cultural shift away from dependency on doctors 
and drugs to solve problems,” says Robert D. Kerns, 
Ph.D., a research psychologist at VA Connecticut 
Healthcare System, West Haven Campus, and professor 
of psychiatry, neurology, and psychology.
Other Yale researchers are exploring non-addictive 
drug therapies that may eventually replace opioids for 
some uses. Stephen Waxman, M.D., Ph.D., the Bridget 
M. Flaherty Professor of Neurology, and director of the 
Center for Neuroscience and Regeneration Research, is 
working with pharmaceutical companies to develop 
drugs that block sodium channels, which transmit 
pain impulses through the nervous system (see story 
on page 18).
changing attitudes
In the meantime, Yale’s addiction experts believe it will 
be difficult to address today’s opioid epidemic without 
changes in attitudes. To many people, addiction signals 
a personal failing. Too often, those with drug problems 
are shunned or treated like criminals, or they try to 
hide their problems rather than seek help.
To meet Rachel Moore (not her real name), you 
would never suspect that she’s recovering from heroin 
addiction. The 29-year-old lab tech in New Haven is 
bright and cheerful, and loves her job. She started 
shooting heroin at age 16 “to fill a hole” in her life. 
Now, after 11 years of methadone treatment and coun-
seling, no relapses, and two college degrees, she’d like 
to help break the stereotypes about drug addiction. Yet 
none of her work colleagues know her secret. “Maybe if 
I was more open and told people my story, I could help 
change attitudes,” she says. “But I’m worried it would 
change the way people viewed me. I think people for-
get there is a unique individual behind the addiction.” 
Heimer of the School of Public Health says it’s time 
for our society to replace shame with empathy and 
understanding of addiction as a chronic relapsing dis-
ease. “We have to reduce the stigma associated with 
addiction,” he says. “We have to stop calling people 
names. They’re not ‘junkies’ or ‘addicts.’ They’re 
people with a disease, and we have to get them into 
treatment.” /yale medicine magazine
Steve Hamm is a contributor to Yale Medicine Magazine.
17Winter 2018
ymm.yale.edu18
How a Yale scientist is looking for  
painkillers that target sodium channels, 
not opioid receptors
by ashley p. taylor | greg hall illustration
Alternatives to opioids
Opioids block pain signals by stimulating opioid recep-
tors in the spinal cord and brain. But they don’t work for 
all types of chronic pain, says Stephen Waxman, M.D., 
Ph.D., the Bridget M. Flaherty Professor of Neurology 
at Yale School of Medicine and director of the Center 
for Neuroscience and Regeneration Research at the VA 
Connecticut Healthcare System in West Haven. Many 
patients with neuropathic pain—the result of nervous 
system injury or dysfunction—get little or no relief. 
Neuropathic pain, says Waxman, is “a very impor-
tant unmet medical need.” It can occur after nerve 
injury or shingles; in association with diabetes; or as a 
response to chemotherapy.
“For all of these diseases, a common thread is that we 
need better therapies,” Waxman says. He’s working to 
develop such therapies, and he’s found a new target—not 
opioid receptors but sodium channels, which neurons 
need to fire. 
For several years he’s been testing painkillers that 
block sodium channels in patients with a rare genetic 
disorder that sends their pain neurons into overdrive. 
Waxman hopes to find treatments that will not only 
ease common types of chronic pain but also reduce opi-
oid use.
His search for non-opioid painkillers began at the 
dentist’s office. Lidocaine, Novocaine, and all of the 
“-caine” drugs in dentists’ needles are local anesthetics 
that stop neurons from transmitting pain signals by 
blocking their sodium channels. But in pill form, those 
drugs would have such unacceptable side effects as 
double vision, seizures, sleepiness, and confusion, all a 
consequence of blocking sodium channels in the brain. 
A “holy grail of pain research,” Waxman says, is to find 
a sodium channel that is essential to the function of 
peripheral nerves that lie outside the brain and spinal 
cord, but that does not play a major role in the brain. 
Exploiting such a channel, he says, could block pain 
without leading to side effects or addiction. 
In the 1990s, scientists found such a channel, Nav1.7, 
and Waxman’s lab began to study it. But drug com-
panies wouldn’t pursue drugs targeting that channel 
without proof that it had an important role in human 
health. In 2003 Waxman began scouring the world for 
people with inherited neuropathic pain, in hopes of 
linking pain disorders to their particular mutations, 
genes, and proteins.
He was still searching when a lab in China reported 
in March 2004 that mutations in a gene, SCN9A, which 
encodes Nav1.7, were the likely cause of the rare genetic 
disorder inherited erythromelalgia (IEM). “Mild warmth 
triggers intense burning pain, and many patients keep 
their hands and feet on ice, to the point of getting tissue 
damage, sometimes even gangrene,” Waxman says of 
the disorder, also known as man-on-fire syndrome. At 
Alternatives to opioids
Since ancient times, humans have used opium  
and its derivatives to block pain. Yet in all that 
time, no one has found a solution to two main  




































first Waxman thought that the Chinese lab had beaten 
him to the punch. But although the Chinese scientists 
had linked the sodium channel to the disorder, they 
had not shown how the channel works or how damage 
to the sodium channel causes IEM. The Waxman lab 
began investigating and later that year published their 
results. The mutations in SCN9A, says Waxman, “make 
the Nav1.7 channel overactive. And that makes pain-
signaling nerve cells shriek when they should be whis-
pering.” Soon, Waxman’s lab received a grant from The 
Erythromelalgia Association and what Waxman calls “a 
much bigger gift”—access to a community of families 
with erythromelalgia who have shared their DNA and 
medical histories and participated in clinical trials.
In 2009 Waxman and colleagues reported that 
patients with a particular SCN9A mutation responded 
well to carbamazepine, which blocks all sodium 
channels. Later, they used computer modeling of the 
sodium channel to predict that people with IEM who 
had a different SCN9A mutation might also respond to 
the drug. A 2016 study at Yale confirmed their hypoth-
esis. Waxman hopes to use genetics and computer 
modeling in a “precision medicine” approach to pre-
dict drug responses in patients with other variations in 
their genes. 
In 2016, Waxman collaborated with Pfizer to test 
another drug that, unlike carbamazepine, targets only 
the sodium channel Nav1.7. Three of the five study par-
ticipants responded to the drug in at least one of two 
trials, and two participants responded to the drug on 
both trials. In general, patients reported a three-point 
reduction in pain on the 10-point scale. Waxman cau-
tions that the number of patients studied was small. 
Nevertheless, “That’s a fairly large improvement,” 
Waxman says. 
The scope of this research extends beyond IEM. 
Waxman hopes that work on sodium-channel block-
ers will lead to the development of non-opioid medi-
cations to treat many kinds of chronic pain. Already 
the British company Convergence Pharmaceuticals, 
recently acquired by Biogen, has tested one Nav1.7 
blocker as a treatment for trigeminal neuralgia, 
which causes attacks of facial pain. Waxman is collab-
orating on that study, and early results are promising, 
he says. Eventually, Waxman believes, these opioid 
alternatives will be tested as treatments for back pain, 
diabetic neuropathy, and more. “We need to do a lot 
more work, and the numbers will tell the story, but  
I am hopeful.” /yale medicine magazine
Ashley P. Taylor is a frequent contributor to Yale Medicine Magazine.
Atomic-level model of the 
Nav1.7 sodium channel, 
which is a master switch for 
pain. This model is permit-
ting scientists at Yale to 
advance  toward “precision,” 
genomically guided medica-
tions for pain, which will not 
have such side effects as 
sleepiness or confusion, and 






































Each year substance use disorder robs millions  
of people of health, self-respect, and even life. 
Patients who make their way to treatment follow  
an arduous path.
by jenny blair, md ’04 | greg hall illustration
The road back to 
good health
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Next, Kevin became a successful salesman of automatic 
doors. Even as his business thrived and he found himself 
in demand as an expert witness in automatic-door liabil-
ity cases, he began to drink alone in hotels. 
Then a $50 million lawsuit hit. It ruined his finances 
as well as his marriage. 
“That’s when my alcoholism really started to flour-
ish,” says Kevin, now a 64-year-old retiree living in New 
Haven. “I came back up north, broke, enraged, and just 
kept drinking and drinking. My whole family didn’t 
want me around.” Often homeless, hospitalized, or in jail, 
Kevin spent over seven years in and out of the Yale ED. 
And it was in the ED that Kevin connected with Project 
ASSERT—and turned his life around. 
The project’s deceptively simple mission: to screen 
patients for substance use disorders, conduct a brief 
negotiation interview, and refer patients to treatment 
(a trio of actions abbreviated to SBIRT). It staffs the EDs 
of both Yale New Haven Hospital (YNHH) and the Saint 
Raphael campus with Health Promotion Advocates 
(HPAs) trained to conduct the short interviews, which 
help patients explore the pros and cons of substance use, 
and begin to think about the possibility of change. For 
those who feel ready, project staff can arrange for trans-
fers to detox or rehab directly from the ED. Since the 
program’s founding, it has arranged treatment for some 
48,000 people. “We are their voice in the ED,” says HPA 
Shevonne Mack. 
In 2016, of all the patients the HPAs met with in 
the ED, 22 percent went straight into treatment, while 
another 43 percent received treatment referrals. Getting 
people the substance abuse treatment they need is not 
only good patient care and good public health, resulting 
in fewer ED visits due to injury, it may also be good eco-
nomics. One 2005 study found that an ED-based program 
saved $3.81 for every $1.00 it spent on an SBIRT program. 
Gregory Johnson is a founding member of Project 
ASSERT and one of several HPAs who worked with Kevin. 
Johnson attributes the project’s successes to its home base 
in the ED. Accosting people with substance use disorders 
on the street may or may not lead anywhere—it’s all too 
easy to toss an informational flyer, for instance. But an 
ED visit can bring long waits and time for reflection—the 
perfect opportunity for a caring outsider to offer help.
“If the patient recognizes that he has arrived at the 
chest pain center because of cocaine and alcohol use and 
I tell them ‘I can get you directly into treatment from the 
ED, from point A to point B’, they’re more likely to say, 
‘Let’s go for it,’ ” Johnson says.
The project began in 1999 as a one-year, grant-funded 
initiative to help people with substance problems self-
reflect via the brief negotiation interview. Within a few 
months, its mission grew, according to Johnson. Not only 
were HPAs finding at-risk drinking and drug use, they 
were uncovering severe substance use disorders. 
The normal procedure in such cases was to alert 
social workers, who would refer patients for treatment. 
But social workers often did not show up in the ED 
when called, Johnson says. So he took matters into his 
own hands. Having previously worked at New Haven’s 
South Central Rehabilitation Center, he knew how 
to get people into treatment, and he started doing so. 
After the grant ran out, the hospital hired the team as 
permanent employees. 
The road back to good health
Before Kevin M.’s drinking problem began, before he 
became what he calls a “frequent flyer” in the Yale New 
Haven Hospital emergency department (ED), he was 
a policeman in Hollywood, Florida. There, he became 
involved in several shooting incidents. Though a civilian 
review board determined he had been justified, he says, 
he was asked to “leave the department quietly.”
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For Kevin, an HPA’s words at a crucial moment made 
all the difference. One morning, he went to Yale New 
Haven Hospital to collect belongings he’d left during a 
discharge the previous day. He planned to hit the liquor 
store next. But as he waited in the hospital atrium, one of 
the HPAs spotted him and came to say hello. She asked 
him if he’d been drinking that morning. He had.
“She sat and talked to me,” he recalls. “Something 
went on in my head that said, ‘Are you ready to stop?’ ” 
Kevin walked to the ED, where his blood pressure and 
heart rate were found to be sky-high. That morning’s 
drink turned out to be his last. After his discharge, he 
became deeply involved with Alcoholics Anonymous. No 
longer homeless, he spends up to four days a week at Yale 
New Haven Hospital and the Saint Raphael campus, talk-
ing with others who struggle with alcoholism. 
“I try to give them what was given to me, which is that 
little light in your head that’s in that very dark place that 
“We became the substance treatment people,” 
Johnson says. 
In addition to short detox programs for the physi-
cally addicted, HPAs also arrange longer stays in rehab. 
Project ASSERT also emphasizes harm reduction, offering 
naloxone antidote kits, suboxone, and methadone clinic 
appointments for some patients. 
The idea of bringing public health initiatives like 
this to the ED is partly that of Gail D’Onofrio, M.D., 
M.S., the chief of Emergency Services. D’Onofrio is a 
renowned federally funded SBIRT expert who sees to it 
that all primary-care resident physicians at Yale learn 
the technique. 
The HPAs credit much of their success to personal con-
nections—among the community as well as to the patients 
they serve. Being on a first-name basis with rehab and 
detox workers all over the state can often open doors, for 
instance, especially for patients whose insurance doesn’t 
  Gregory Johnson
 “If I say I can provide immediate help  
  for them, and I actually come through on 
my word, that leaves an imprint on them. 
cover treatment or who lack it altogether. And, recogniz-
ing patients’ difficult life circumstances, which can make 
relapse hard to avoid, the team also works to connect them 
to other area resources wherever possible. 
That personal connection with patients can be espe-
cially important after relapse. Those who decide to try 
again often ask for help from an HPA they’ve come to trust.
“I’ve had patients who call their mother and their 
mother hangs up on them because they burned so many 
bridges,” Johnson says. “If I say I can provide immediate 
help for them, and I actually come through on my word, 
that leaves an imprint on them.”
says, ‘You don’t have to live this way anymore,’ ” Kevin 
says. “That’s what the folks over at the ER with the proj-
ect over there do. … They never gave up on me.”
“You can’t be judgmental, and you’ve got to be  
compassionate, and you’ve got to understand it’s a  
disease,” says HPA Damaris Navarro. “They come  
back, they’re going to come back, but that’s a part of 
getting better.” /yale medicine magazine
Jenny Blair, M.D. ’04, a freelance writer based in Montpelier, Vermont, 
has written frequently for Yale Medicine Magazine.
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For as long as they’ve had the ability,  
humans have sought natural sources for 
stimulation and relief from pain and injury.
compiled by adrian bonenberger
History of substance abuse
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7,000–5,000 BCE Grapes 
cultivated for wine in what is 
now modern-day Georgia. And 
they’re still making wine out-
side Tblisi today!
5,000 BCE Likely oral origins 
of the Ayurveda, Hinduism’s 
traditional medical system, in 
which alcohol is prescribed 
as a cure for certain ailments, 
but not in excessive quanti-
ties—too much use of alcohol 
is seen as damaging.
3,400 BCE The opium poppy 
is cultivated in lower Meso-
potamia. Sumerians refer to it 
as Hul Gil, the “joy plant.” The 
Sumerians would soon pass 
along the plant and its eu-
phoric effects to the Assyrians. 
The art of poppy-culling would 
continue from the Assyrians 
to the Babylonians, who in turn 
would pass their knowledge 
on to the Egyptians.
12th century BCE Early refer-
ences to “drink madness” from 
ancient Egypt and Greece. 
9th century BCE In Homer’s 
Odyssey, Helen is described as 
giving soldiers and veterans 
of the Trojan War drugged 
wine according to a recipe 
discovered in Egypt—a magi-
cal potion called Nepenthes 
pharmakon, or the anti- 
sorrow drug. 
5th Century BCE Herodotus 
makes references to drunken-
ness as a sickness of body  
and soul.
4th Century BCE Aristotle  
(384–322), in comparing 
licentiousness to drunkenness, 
noted that the former was a 
functional disorder while  
the latter resulted from an 
organic disorder. He viewed 
licentiousness as permanent, 
but drunkenness as curable.  
When Alexander the Great 
(Aristotle’s most famous  
pupil) died in 323 BCE, his death 
was ascribed partly to years of  
immoderate drinking.
1st Century BCE The Yellow 
Emperor’s Classic of Internal 
Medicine, an organized and 
systematic explanation of 
acupuncture recognizable to 
practitioners today, is published 
in China. “These days, people 
have changed their way of life,” 
says the Yellow Emperor Huang 
Di in the opening chapter. “They 
drink wine as though it were 
water, indulge excessively in 
destructive activities, drain 
their jing (the body’s essence 
that is stored in the kidneys) 
and deplete their qi [life force].” 
The text treats alcoholism (and 
other diseases or ailments) as a 
behavioral problem, and recom-
mends adjusting one’s behavior 
to compensate. 
98 AD Tacitus writes in 
Germania, that German tribes 
“ do not show the same self-
control in slaking their thirst. 
If you indulge their intemper-
ance by plying them with as 
much drink as they desire, they 
will be as easily conquered by 
this besetting weakness as by 
force of arms.”
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1st Century AD The Roman 
philosopher Seneca (4 BCE–
65 AD) defines drunkenness 
as a type of insanity. “The 
word drunken is used in two 
ways—in the one case of a 
man who is loaded with wine 
and has no control over him-
self; in the other, of a man who 
is accustomed to get drunk, 
and is a slave to the habit … 
there is a great difference 
between a man who is drunk 
and a drunkard.”
 4th Century AD St. John 
Chrysostom compares inebria-
tion to other known diseases. 
He is, however, in favor of 
using wine because of its 
sacramental role in the Eucha-
rist and its centrality in one of 
Jesus’ best-known miracles.
5th century AD St. Bene-
dict writes the Rule of Saint 
Benedict, in which alcohol is 
not prohibited. He notes that 
monks who abstain from alco-
hol tend to be more virtuous.
6th century AD Germanic 
tribesmen prone to abusing 
alcohol or drugs are encour-
aged to binge before battle. 
Wearing wolf or bear skins, 
given plenty of space by 
their allies, these men were 
deployed as berserkers (from 
the Norse word for bear 
shirt) and feared by their en-
emies. Three of these tribes, 
the Angles, Saxons, and 
Jutes claim Britain between 
450 and 550 AD.
7th century AD Islam 
founded. Islam’s attitude 
toward alcohol differs  
from that of Christianity. 
Lacking the New Testament 
descriptions of Christ’s use 
and blessing of wine, Islam  
is free to prohibit alcohol 
completely, a prohibition 
that stands to this day. 
Although the prohibition 
broadly concerns “intoxi-
cants,” thus providing a reli-
gious rationale for banning 
narcotics as well, early  
Islam seems to have been 
less strict in its attitude 
toward the consumption 
of nonalcoholic substances, 
including coffee.
The Middle Ages (5th–
13th century AD) attitudes 
toward drunkenness varied. 
Some religious sects prohib-
ited the use of substances 
(the Ismaili Naziri or “Assas-
sins”), while others permitted 
or encouraged it (Benedictine 
and Francescan monks); use 
varied by culture and reli-
gious context. Overall, ad-
diction was regarded as vice, 
and treatment was either 
nonexistent or focused on 
spiritual redemption.
11th–12th century AD Medi-
cal students from Salerno, 
Italy, build the first stills, en-
abling the distillation of spir-
its. This greatly increased 
the potency of beverage 
alcohol and spurred a world-
wide surge in alcoholism.
12th–13th century Zhang 
Sanfeng, whose exercises 
allowed him to (allegedly) 
live 152 years, establishes 
the basis for Tai Chi, which 
does not recognize a division 
between the physical body 
and the spirit. In addition to 
exercises, Sanfeng’s teach-
ing recommends abstaining 
from alcohol, meat, beans, 
and grains.
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14th century Italian scholar 
Petrarch’s rediscovery of 
humanist, pagan texts from 
classical thinkers lays the 
groundwork for the Renais-
sance and the Enlightenment. 
Humanist scholarship also 
plays a major role in the Prot-
estant Reformation. While 
some Protestant churches 
(Lutheran, Anglican) continue 
to permit the use of alcohol, 
others adopt strict prohibi-
tions against its use, including 
some of the smaller groups 
that help establish the English 
colonies of North America.
1517 Sigismond de Dietrich-
stein organizes the Order of 
Temperance in Germany. The 
order calls for an end to the 
custom of “pledging healths” 
(toasts)—a practice thought 
to promote intemperance.
1560s–90s An early descrip-
tion of narcotic withdrawal, 
cravings, and compulsions: 
European explorers and scien-
tists, in describing the opium 
traffic among the Turks, Chi-
nese, Moors, and Persians, note 
of opium consumers: “If they 
leave off somewhat taking it, 
then they feel physically ill.” 
1600 Dietrichstein’s Or-
der of Temperance allowed 
members no more than seven 
alcoholic drinks per meal, and 
only two meals per day. Well, 
as the saying goes: “you have 
to start somewhere.” 
1606 Shakespeare’s Macbeth 
offers a guarded evaluation of 
the ills of drink—Lady Macbeth 
drinks for courage to assas-
sinate (“That which hath made 
them drunk hath made me bold; 
what hath quenched them 
hath given me fire”) while King 
Duncan and his guards have be-
come vulnerable through drink. 
The play may reflect evolving 
Elizabethan attitudes toward 
drunkenness. Alcohol was not 
viewed as the problem, but 
rather human dependence on it 
for comfort. Drunkenness was 
therefore a sign of moral weak-
ness rather than disease.
1620 Separatists, members 
of a Puritan sect, settle New 
England, and bring judgmen-
tal attitudes toward the use of 
substances with them.
1747 The French philosopher 
Condillac refers to inebriety 
as a disease and calls for 
state-sponsored treatment.
1772 Physician and social re-
former Benjamin Rush calls for 
the abandonment of distilled 
spirits and the substitution  
of cider beer, wine, and non-
alcoholic drinks in his sermons 
to Gentlemen Upon Temper-
ance and Exercise. Later, he 
calls for the creation of special 
hospitals for “inebriates,” fol-
lowing the notion that drink 
(and not the drinker) was to 
blame for alcoholism.
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1787–1813 Delirium tremens 
(acute alcohol withdrawal syn-
drome) recognized and medi-
cally described by Lettsom, 
Armstrong and Pearson, and 
then named by Thomas Sutton.
1789 First American temper-
ance society organized in 
Litchfield, Connecticut.
1799 China’s emperor, Kia King, 
bans opium, making trade and 
poppy cultivation illegal.
Early 1800s In Boston, tem-
perance advocates found a 
brewery to provide beer to 
those who pledged to forsake 
“ardent spirits”—what we call 
hard liquor.
1811 A temperance society in 
Fairfield, Connecticut calls for 
total abstinence, acknowledg-
ing that this is a harsh remedy, 
“but the nature of the disease 
absolutely requires it.”
1819 Christopher Wilhelm 
Hufeland coins the term dipso-
mania to describe the uncon-
trollable craving for spirits that 
triggers “drink storms.”
1826 American Temperance 




perance (moderation) and 
embraces total abstinence as 
a goal and legal prohibition of 
alcohol as a means of collec-
tively achieving that goal. 
1830 The Connecticut State 
Medical Society calls for cre-
ation of inebriate asylums.
1833 Dr. Samuel Woodward,  
superintendent of the 
Worcester Insane Hospital 
and Women’s Lunatic  
Asylum in Massachusetts, 
writes a series of essays that 
are published in 1836 and 
again in 1838. “A large propor-
tion of the intemperate in a 
well-conducted institution 
would be radically cured, and 
would again go into society 
with health reestablished, 
diseased appetites removed, 
with principles of temperance  
well grounded and thoroughly 
understood, so that they 
would be afterwards safe  
and sober men.”
1839 Lin Tse-Hsu, imperial  
Chinese commissioner in 
charge of suppressing opium 
traffic, orders all foreign  
traders to surrender their 
opium. To protect its opium 
trade, the British send ex-
peditionary warships to the 
coast of China, beginning the 
first Opium War. By 1841, the 
Chinese have lost the war, 
and cede Hong Kong to the 
United Kingdom.
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1840–1890 More than 200 
American water cure institu-
tions include alcoholics and 
addicts among their devoted 
clientele and solicit their pa-
tronage through such media 
as The Water Cure Journal.
1849 The Swedish physician 
Magnus Huss introduces 
the term “alcoholism” in his 
text, Chronic Alcoholism; it 
does not appear in the United 
States until after the Civil War. 
1853 The hypodermic sy-
ringe is developed as a refine-
ment of the use of cannulae 
to introduce drugs beneath 
the skin. Morphine is one of 
the first drugs for which the 
syringe is commonly used 
to treat such conditions as 
facial neuralgia.
1856 The British and French 
renew hostilities against Chi-
na during the Second Opium 
War. The import of opium is 
legalized in China again.
1860 Alexander Peddie, a 
Scottish physician practicing 
in Edinburgh, calls for legal 
commitment of dipsomani-
acs to inebriate asylums. He 
distinguished between com-
mon drunkards whose exces-
sive drinking was a vice and 
the “insane drinker” whose 
vice had been transformed 
into a disease no longer under 
his volitional control. Peddie 
believed this disease could be 
inherited or acquired.
1861–65 Widespread use of 
morphine during America’s 
Civil War, along with the in-
troduction of the hypodermic 
syringe, lead to an epidemic 
of opioid addiction among 
veterans of the conflict; so 
much so that opioid addiction 
temporarily becomes known 
as “soldier’s disease.”
1878 Britain passes the Opi-
um Act with hopes of reduc-
ing opium consumption. The 
selling of opium is restricted 
to registered Chinese opium 
smokers and Indian opium 
eaters, while the Burmese  
are strictly prohibited from 
smoking opium.
1890 The U.S. Congress, in 
its earliest law-enforcement 
legislation on narcotics, 
imposes a tax on opium and 
morphine. Tabloids owned 
by William Randolph Hearst 
publish stories of white 
women being seduced by 
Chinese men and their opium 
to invoke fear of the yellow 




ing for The Bayer Company of 
Elberfeld, Germany, finds that 
diluting morphine with acetyls 
produces a drug without the 
common side effects of mor-
phine. Bayer begins produc-
tion of diacetylmorphine and 
coins the trade name “Heroin.” 
Within a few years, the philan-
thropic Saint James Society in 
the United States has mounted 
a campaign to supply free 
samples of heroin through the 
mail to morphine addicts trying 
to break their habit. By 1902, 
physicians have begun to note 
in various medical journals the 
side effects of using heroin as 
a morphine step-down cure. 
Several physicians argued that 
their patients suffered from 
heroin withdrawal symptoms 
equal to morphine addiction.
1905 U.S. Congress bans opium.
1906 Several physicians 
experiment with treatments 
for heroin addiction. Alex-
ander Lambert and Charles 
B. Towns tout their popular 
cure as the most “advanced, 
effective, and compassion-
ate cure” for heroin addic-
tion. The Towns-Lambert 
Cure consists of a seven-day 
regimen, which includes 
a five-day purge of heroin 
from the addict’s system 
with doses of belladonna 
(nightshade) that often pro-
duces delirium. The patient 
also receives other drugs 
thought to be beneficial.
1914 The Harrison Narcotics 
Act passes. It requires doctors, 
pharmacists, and others who 
prescribe narcotics to register 
and pay a tax.
1923 The U.S. Treasury De-
partment’s Narcotics Divi-
sion (the first federal drug 
agency) bans narcotics sales. 
As a result, substance users 
are forced to buy from illegal 
street dealers.
1939 The first edition of the 
basic text of Alcoholics Anon-
ymous (AA), notes: “Then we 
have a certain type of hard 
drinker. He may have the habit 
badly enough to gradually im-
pair him physically and men-
tally. It may cause him to die a 
few years before his time. If a 
sufficiently strong reason—ill 
health, falling in love, change 
of environment, or the warn-
ing of a doctor—becomes 
operative, this man can also 
stop or moderate, although 
he may find it difficult and 
troublesome and may even 
need medical attention.”
1944 Two “Yale Plan” clinics 
open in Connecticut, one in 
New Haven and one in Hartford. 
The Clinics hope to develop a 
plan for cost-effective assess-
ment and treatment of people 
suffering from alcoholism.
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1960s Expansion of drug use 
into white middle class youth 
transforms attitudes and ap-
proaches toward treatment. 
Shifting patterns of substance 
use addiction during the 
Vietnam War and Civil Rights 
era lead to a massive cultural 
divide in the U.S., leading to 
a fundamental split between 
conservative and progressive 
lawmakers in their approach 
to treating drug and alcohol 
dependence.
1965-75 Involvement in Viet-
nam is blamed for the surge in 
illegal heroin being smuggled 
into the United States.
1970 The Controlled Sub-
stances Act of 1970 classifies 
marijuana along with heroin 
and LSD as a Schedule I drug—
high abuse potential, with no 
accepted medical use.
1973 President Richard Nixon 
creates the DEA (Drug En-
forcement Administration) 
under the Justice Department 
to consolidate federal pow-
ers of drug enforcement in a 
single agency.
1985–93 New research extols 
the positive effects of moder-
ate drinking; the first “how-to” 
books on controlled drinking  
are published, contributing 
to “Moderation Management,” 
a moderation-based support 
group alternative to AA.
1994 The Clinton Administra-
tion orders a shift in policy 
away from the anti-drug cam-
paigns of previous administra-
tions. Instead focus includes  
“institution building”— 
included harsh sentences for 
repeat offenders (also known 
as the “Three Strikes” law).
2000 The Drug Addiction 
Treatment Act facilitates the 
treatment of chronic opioid 
users by qualified doctors in 
a clinical setting using ap-
proved Schedule III, IV, and  
V narcotics.
2002 Buprenorphine is ap-
proved as a Schedule III drug, 
and becomes the first ap-
proved as safe to use as treat-
ment in a doctor’s office.
With gratitude to William White, MD, 
whose papers and timelines on the subject 
supplied much of the background and 




Non-addictive pain medication has  
changed how experts approach  
therapy for substance use disorders.
by sonya collins | greg hall illustration
How treatment for addiction 
came out of the Dark Ages
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Treatment for opioid use disorder hasn’t always brought 
such clear rewards. Throughout the 1960s, abstinence-
based detox was the only widely available treatment 
despite high relapse rates. Then, in 1965, methadone  
clinics emerged as a game-changer. 
Rockefeller University clinicians Vincent Dole, 
M.D., and Marie Nyswander, M.D., reported in JAMA: 
Journal of the American Medical Association that 
year that they had used once-daily oral methadone—
an opioid painkiller—to stabilize 22 young men who 
were addicted to heroin. Methadone relieved both 
withdrawal and cravings, and allowed patients to 
resume their lives. On September 15, 1969, Robert 
DuPont, M.D., who would become the first director of 
the National Institute on Drug Abuse, started the first 
methadone maintenance treatment program, which 
served 25 parolees in Washington, D.C.
“That is when treatment for opioid use disorder 
emerged from the Dark Ages,” said Patrick G. O’Connor, 
M.D., M.P.H. ’88, FW ’88, the Dan Adams and Amanda 
Adams Professor of General Medicine, and chief of gen-
eral internal medicine. 
As methadone clinics opened in cities around the coun-
try, studies showed that the treatment decreased drug 
use and opioid overdoses, lowered hepatitis B and C rates, 
improved pregnancy and birth outcomes, increased over-
all survival, and—crucially—lowered risk for HIV infection.
But the groundbreaking treatment wasn’t perfect. 
Patients who landed a coveted spot in one of a handful of 
licensed clinics had to show up every day for their dose 
until they were deemed trustworthy enough to take a sup-
ply home. That process could take months. As heroin users 
tried to escape the soaring risk of HIV infection in the late 
1980s, the model could barely support the demand. 
“Here in New Haven, we had waiting lists of six 
to 12 months for a slot in a methadone clinic,” said 
O’Connor. “People were literally dying while they were 
waiting for this highly effective treatment.”
O’Connor and colleagues at Yale knew there had to 
be a better way. “What if we developed an approach to 
treating opioid dependence that didn’t rely on one or 
two methadone programs in New Haven, but rather was 
available in primary care clinics and physicians’ offices 
all over the city?” O’Connor asked. 
chronic care for addiction
In a 1992 article in the Journal of General Internal 
Medicine, O’Connor and colleagues showed that they 
could manage withdrawal from heroin with clonidine, 
a drug introduced in 1966 to treat high blood pres-
sure and that was found to manage opioid withdrawal. 
Once opioid-free, patients received naltrexone, an opi-
oid blocker which renders them less able to feel “high” 
or to overdose when they use heroin. Theoretically, the 
medication would eliminate the stimulus to use opi-
oids. But cravings persisted and patients often gave up 
naltrexone and returned to using opioids. 
Still, says O’Connor, “We showed that patients 
would come to primary care for treatment and that 
we had an effective protocol that could get them to a 
drug-free state in an outpatient setting.” Integrating 
addiction treatment into primary care has additional 
benefits. This model would allow patients to receive 
both addiction treatment and general medical care 
How treatment for addiction came out of the Dark Ages
“It’s not often that a psychiatrist gets to hear ‘Doctor, 
you saved my life,’ ” said Ellen Edens, M.D., FW ’09, 
assistant professor of psychiatry and associate fellow-
ship director in addiction psychiatry. But she gets that 
a lot from patients receiving outpatient treatment for 
opioid use disorder. “They tell me, ‘I have my children 
back, I’m working, I feel good.’ ”
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of this neglect, physicians who want to treat patients 
with buprenorphine must first attend an all-day 
course. Federal law limits them to treating up to 
275 patients at a time in a “qualified setting” that com-
plies with information technology requirements and 
makes counseling services available. For practical rea-
sons clinicians rarely if ever treat the full 275 patients 
allotted to them.
“It sends a message to physicians,” said Edens, “that 
this is a dangerous or abusable system, but buprenor-
phine is so easy to use, and when it’s misused, it’s usually 
for the exact reason we would use it: to treat withdrawal.”
But treatment for opioid use disorder won’t stop, 
now that it’s treated as a chronic condition in an 
outpatient setting in a manner similar to such other 
chronic diseases as diabetes. “As with any other 
chronic disease,” said O’Connor, “we’ll continue to 
search for new and more effective medication and 
psychosocial treatment approaches to improve health 
and save lives.” /yale medicine magazine
Sonya Collins is a freelance writer in Atlanta, Georgia.
“under one roof,” without the stigma of an addiction 
treatment program.
Because patients often abandoned naltrexone, 
O’Connor explored a new approach—using opioid main-
tenance therapy in primary care. Since methadone 
could be used only in specialized programs, he per-
formed the first randomized trial of primary care-based 
buprenorphine—an experimental medication that had 
been found as effective as methadone in specialized 
treatment programs. 
“Our study found that patients who received 
buprenorphine in primary care did just as well as those 
who received it in specialized addiction treatment set-
tings,” said O’Connor. 
Soon, the Drug Addiction Treatment Act of 2000 
permitted physicians who met certain criteria to 
treat opioid addiction in outpatient offices using FDA-
approved Schedule III, IV, and V narcotics, although 
none were available at that time. Two years later, the 
FDA approved two drugs that fit the bill. 
Subutex (buprenorphine hydrochloride), the partial 
opioid agonist that O’Connor studied, could alleviate 
withdrawal and cravings with less risk of overdose or 
abuse than methadone. Suboxone (buprenorphine hydro-
chloride and naloxone hydrochloride) added naloxone to 
decrease the risk of misuse. Both formulations could be 
administered in a doctor’s office. 
Medication-assisted therapy—Subutex or Suboxone 
in addition to such psychosocial treatment as counsel-
ing—became the standard of care. “It was revolution-
ary,” said Edens. “One patient could be waiting to get 
their blood pressure checked next to another who is 
waiting to get Suboxone for opioid use disorder, and 
nobody knows the difference.”
Researchers, including David A. Fiellin, M.D., HS ’94, 
FW ’96, professor of medicine, challenged a long- 
standing belief when they began to show that treatment 
with buprenorphine combined with primary care phy-
sician management was as effective as buprenorphine 
combined with cognitive behavioral therapy. 
aligning evidence with policy
While treatment has advanced over the last 50 years, 
policy and medical education lag. Medical school cur-




More than six months after his paper on his new 
treatment for babies born to mothers addicted to opi-
ates appeared in the journal Pediatrics, Matthew 
Grossman, M.D., HS ’06, assistant professor of pedi-
atrics, is seeing his methods slowly but steadily take 
hold. [See “More mom, fewer drugs,” Yale Medicine 
Magazine, Autumn 2016].
Boston Medical Center and Christus Regional 
Medical Center in Santa Fe, New Mexico, have adopted 
his approach, which reduces babies’ withdrawal time 
by replacing drug therapy with increased contact 
with their mothers. Hospitals in Camden, New Jersey, 
and Canada, and state health collaboratives in New 
Hampshire, Vermont, Maine, and Maryland are all 
talking to him about introducing the protocol. Articles 
highlighting his methods have appeared in The New 
York Times and other publications. Inquiries from medi-
cal institutions have grown over the past 18 months 
from infrequent to one or two a week in 2017, and 
Grossman has traveled extensively to give talks and help 
with implementation. “I don’t say no,” he says.
While he is gratified by the growing recognition 
and use of his treatment, Grossman wishes it would be 
adopted more quickly. Additional data collected at Yale 
New Haven Hospital and other institutions have only 
confirmed how well it works, he says.
Grossman’s key insight came in 2009 when he real-
ized that babies who spent more time with their mothers 
left the hospital after an average of 22 instead of 29 days. 
That flew in the face of the all-but-universal and long-
standing practice of taking babies born addicted to opi-
ates from their mothers, putting them in intensive care, 
and following a rigid protocol to assist their withdrawal 
from morphine and other drugs. Grossman and his team 
at Yale New Haven Hospital started experimenting to 
see whether even more time with mom would further 
speed withdrawal. The results were dramatic: the average 
hospital stay plummeted by more than two-thirds to just 
5.9 days, with most of the infants needing far less, (if any), 
medication. “More mom, fewer drugs,” is how Grossman 
sums it up. 
Grossman is now working on a second paper that 
expands on and reinforces his findings. He and his 
team compared their actions under the new method 
with the traditional method, the Finnegan Neonatal 
Abstinence Scoring System. That method tracks 29 
symptoms to determine whether a baby should receive 
morphine or another drug. They found improvement, 
for example, in 70 percent of babies who would have 
received medication under the old system. Amazingly, 
the Finnegan scoring method has never been exten-
sively studied, he said.
Other works in progress include following the 
babies to see how they do long term—Grossman has 
met with the Yale Child Study Center about setting up 
a monitoring program—and ensuring that the infants 
receive any necessary services. 
In retrospect, Grossman finds it amazing that hos-
pitals have for so long used and continue to use the 
Finnegan method. “The idea that we were separating 
these babies from their source of love and their family 
just seems terrible,” Grossman says, sitting in his narrow, 
unadorned office at Yale New Haven Children’s Hospital. 
“We have something that’s really good for babies and 
really good for moms, really good for everyone. We think 
it’s a much better way.” /yale medicine magazine
Christopher Hoffman is a freelance writer in North Haven, Connecticut.
Spreading a Yale pediatrician’s intuitive, unorthodox, 
effective treatment for opioid-dependent newborns.
by christopher hoffman | greg hall illustration
A mother’s love
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About two years ago the 
Medical Historical Library 
began adding a new cat-
egory to its collection of 
scholarly tomes and ancient 
treatises—comic books. 
Along with the works of 
Osler and Vesalius, library 
shelves now house issues of  
Real Life Comics that  
tell stories like “Edward 
Jenner, Plague Fighter,” 
“The Conquest of Yellow 
a question for which 
there is little historical 
documentation.
“How do we know 
what ordinary people and 
patients thought about 
medicine, how they envi-
sioned it, and what their 
attitudes toward it were?” 
said Bert Hansen, Ph.D., 
professor emeritus of the 
history of medicine and 
science at Baruch College 
Fever,” and “The Story  
of Medicine.” 
The comics are now 
source material for an 
undergraduate course 
on medicine and the 
media, and are available 
to researchers exploring 
in New York, and the 
donor of the comic books. 
“Published imagery in 
popular journals and maga-
zines would be an impor-
tant source of evidence.”
Hansen began collecting  
comic books in the 1980s 
after shifting his re-
search from 14th-century 
medicine. Advances 
in medicine—stories of 
medical progress and 
breakthroughs like Walter 
Reed’s vanquishing of 
yellow fever in Cuba and 
Edward Jenner’s discovery 
of vaccination to prevent 
smallpox—found their way 
into the popular imagina-
tion. By the 1920s, medical 
stories had become fod-
der for novels like Sinclair 
Lewis’s Arrowsmith. In the 
1930s and 1940s Hollywood 
joined in with movies 
like Dr. Ehrlich’s Magic 
Bullet, which dramatized 
a cure for syphilis. And in 
their Golden Age in the 
1940s, comic books rhap-
sodized about the likes of 
Louis Pasteur, Alexander 
Fleming, Howard Florey, 
and Clara Barton. 
“The narrative of my 
book, Picturing Medical 
Progress from Pasteur to 
Polio,” said Hansen, “is the 
story of how we get the idea 
of medical progress and 
medical breakthroughs.”
To be sure, the comic 
books took some license 
in focusing on the eureka 
   In their Golden Age in the 1940s, comic books  
 saluted medicine and public health … and paved the  
   way for improvements in human welfare.
  By John Curtis
  Real Life Comics,  
Advocates for Medicine  
 and Public Health
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capsule
moments rather than long, 
fruitless days in the lab. 
And, added John Warner, 
Ph.D., chair and Avalon 
Professor of the History  
of Medicine, the stories  
often portrayed an “under- 
dog,” a scientist with an 
unconventional idea buck-
ing the establishment, and 
“this notion of a break-
through moment.”
Even as medical and sci-
entific accuracy took a back 
seat to a good yarn, Warner 
said, this populariza-
tion helped make medical 
progress possible by lion-
izing heroes of medicine, 
research, and public health. 
Their stories helped lay the 
groundwork for clinical tri-
als of the Salk polio vaccine 
in the 1950s. “[The trials] 
very much depended on 
public health education and 
the expectation of medical 
progress and medical citi-
zenship,” Warner said.
About seven years 
ago, Warner and Gretchen 
Berland, M.D., associ-
ate professor of medicine, 
launched a course in 
which Yale College stu-
dents would explore how 
the public has viewed 
medicine over the years—
Media and Medicine in 
Modern America. Along 
with lectures and ses-
sions with teaching 
assistants in history, law, 
medicine, and public 
health, the course includes 
imagery that include com-
ics, magazines, and post-
ers. Among the questions 
posed are how media por-
trayals shape perceptions 
of the medical profession 
as well as perceptions of 
health and illness within 
the medical community.
The course is one of 
the reasons that Hansen 
donated his collection to 
the School of Medicine. He 
knew Warner from profes-
sional conferences, but he 
During their Golden Age 
in the 1940s, comic books 
went beyond Superman 
and Batman to tell the 
stories of unsung heroes in 
such fields as medicine and 
public health. These heroes 
solved medical puzzles 
and surmounted obstacles 
to improve medicine and 
save lives. Their stories 
popularized medicine and 
public health and, scholars 
say, inculcated the notion of 
“medical citizenship.”
TOP Real Life Comics issue 
of April 1946 told the story 
of Stephen Smith, a reform-
minded doctor in New York 
City during the 19th century, 
who campaigned for clean-
er cities, public housing, and 
public health. His advocacy 
led to the founding of the 
Metropolitan Health Board 
in New York.
BOTTOM Ronald Ross, a 
British physician in India, 
and Giovanni Battista 
Grossi, an Italian physician, 
separately demonstrated 
the role of mosquitoes 
in the transmission of 
malaria. Marvels of Sci-
ence told their story in 
November 1943.
OPPOSITE PAGE, LEFT In 
May 1946, Science Comics 
told the story of Horace 
Wells, a dentist who 
realized that nitrous oxide, 
also known as laughing 
gas, could lead to painless 
dentistry and surgery.
OPPOSITE PAGE, RIGHT  
The summer 1946 issue  
of Picture Stories from 
Science described how 
Walter Reed conducted 
experiments with human 
volunteers to defeat the 
scourge of yellow fever.
a visit to the historical 
library. There, Melissa 
Grafe, Ph.D., the John 
R. Bumstead Librarian 
for Medical History, and 
Susan Wheeler, curator of 
prints and drawings and 
historical medical posters, 
lead the students through 
displays of popular health 
also knew that the School 
of Medicine has a vigorous 
program in the history of 
medicine and faculty who 
are interested in media. 
“I felt that the comics 
would be preserved and 
actually used,” Hansen 































 Riding for 
all the right reasons
»
six flats, three chains, two tires. Five thousand 
one hundred miles, two legs, one patriotic and philan-
thropic Yale physician. Those numbers sketch the cross-
country odyssey of Andrés Martin, M.D., M.P.H. ’02, the 
Riva Ariella Ritvo Professor in the Child Study Center and 
professor of psychiatry, who climbed onto a bicycle on 
August 17 in Seattle, Washington, and arrived over two 
months later in Washington, D.C., no worse for wear. 
Academy of Child and Adolescent 
Psychiatry (AACAP). The organi-
zation represents what he calls 
one of medicine’s most under-
served specialties.
“The need is huge—even if we 
quintupled the number of child 
psychiatrists, it wouldn’t be 
close to enough,” said Martin. 
The money raised by the ride 
will support research and help 
to train new child psychiatrists, 
as well as assisting children 
with mental illness to access the 
care they need.
A typical day on the road saw 
Martin up by 5 a.m., climbing 
onto his carbon-fiber Trek bike 
by 7, and pedaling until midaft-
ernoon—about 100 miles a day. 
Every evening, the experienced 
triathlete climbed into an ice 
bath to protect his legs from 
inflammation, a routine so 
effective that he never needed 
Tylenol. Martin got lucky with 
the weather, too: in 500 hours 
on the road, he endured only 
about four hours’ rain.
It was also Martin’s first 
journey through the country as 
a naturalized United States citi-
zen. The son of Slovakian Jewish 
Holocaust survivors who emi-
grated to Mexico, he earned his 
medical degree in Mexico City. 
He continued his medical train-
ing at the University of Miami 
and at Massachusetts General 
Hospital before joining Yale’s 
faculty in 1996. 
The trip was a “wonderful, 
very granular way of getting to 
“I loved every minute of it,” 
Martin said. 
The goal of that ambitious ride, 
called Break the Cycle: to raise 
awareness of and funding for 
pediatric mental illness. Along 
the road, Martin was joined by 
a rotating cast of 49 fellow rid-
ers, including physicians and 
family members of children 
with mental illness. They did 
media interviews, held one-off 
fundraising events—including a 
spin class—and ultimately raised 
over $200,000 for the American 
ymm.yale.edu42
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Andrés Martin, M.D., 
M.P.H. ’02, in Boston, 
Massachusetts, near-
ing the end of his epic 
months-long cross 
country bicycle fund-
raiser. Over $200,000 
was donated to Martin’s 
ride on behalf of the 
American Academy of 
Child and Adolescent 
Psychiatry (AACAP), 
and he raised awareness 
about the crucial issue 
of child mental illness,  
as well as how to service 
those children who 
need attention.
began as a personal journey. 
Seven years ago, he took up 
cycling as a way to cope with a 
bout of serious depression, the 
fourth such episode of his life. 
Along with professional help and 
a “dash of apt chemicals,” Martin 
wrote in an AACAP editorial 
called “Cyclotherapy,” cycling 
helped him overcome depression. 
After adding a cross-country trip 
to his bucket list, he realized he 
know the country,” Martin said. 
“I’ve been grateful for all the 
opportunities that America has 
opened for me and for my fam-
ily. I’m incredibly patriotic … . 
Crossing the country coast to 
coast, to feel the textures and 
the smells and the sights, it’s 
really, really deep and meaning-
ful.” Some favorite memories: 
Badlands National Monument  
in South Dakota; a short ride  
in Portland, Oregon, whose pace 
was set by children; a man  
with schizophrenia who 
thanked the cyclists for their 
work on his behalf. 
Martin himself has faced 
















could use the ride to give back to 
his profession.
Given that stigma surround-
ing mental illness adds to the 
difficulty many children face in 
accessing psychiatric care, Martin 
says it’s important to speak 
openly about his own issues. 
“If I as a psychiatrist don’t 
talk about it, who will?” he 
asked. “If all this is about 
stigma, stigma, stigma, and  
we dare not say the dirty name 
of depression or other mental 
illnesses, who will?”
At the end of 2017, Martin 
stepped down after a 10-year 
term as editor of the AACAP’s 
journal. He is also AACAP’s 
secretary-elect and a visiting 
professor at Tel Aviv University. 
In addition to mentorship, 
research, and patient care, 
Martin is a prolific writer with 
many essays and reviews of 
popular and scholarly books 
in publication. He lives in New 
Haven with his wife, Rebecca, 
and their four children. 
Break the Cycle was such 
a success that Martin plans to 
make it a franchise of sorts in 
the child psychiatry commu-
nity. For next year, he’s plan-
ning a two-day journey from 
Vancouver, British Columbia, to 
Seattle. A trip through Sweden 
is also in the works for 2019. 
In the process, Martin hopes 
more of his colleagues will 
begin to think of themselves 
as clinician-philanthropists, 
helping the organizations that 
helped them at earlier stages of 
their careers. 
“The mentorship, training, 
education, and early exposure of 
folks going into this field—that’s 
something that I’m really excited 
about,” he said. “No matter what 
branch of medicine you are in, 
what you’re passionate about, 
there’s a way of giving back.”
—Jenny Blair, M.D. ’04
»
Straddling science  
and spirituality
Anna Yusim, M.D. ’06, a psy-
chiatrist in New York City, has 
spent much of the last decade 
meditating on the often-invisible 
intersection of science and spir-
ituality—that ethereal sense of 
connection to something greater 
than oneself. Yusim herself took 
to science seamlessly, but to spir-
ituality slowly. Now, she’s dem-
onstrating—in her practice and 
her writing—how the two are far 
from mutually exclusive. 
“Science is the study of the 
objective, measureable, quan-
tifiable, testable, repeatable,” 
Yusim said, “and spirituality, 
by definition, is the opposite: 
It’s transcendent, personal, 
immanent, subjective, difficult 
to measure quantifiably.” But 
opposites need not be in con-
flict, Yusim maintains. Indeed, 
their reconciliation is where 
she found her own fulfillment—
and now invites readers to 
find theirs in her debut book, 
Fulfilled: How the Science  
of Spirituality Can Help 
You Live a Happier, More 
Meaningful Life. 
Until her residency at New 
York University in 2006, “living 
spiritually wasn’t a part of who 
I was,” Yusim said. It was, how-
ever, a significant part of how 
her mother saw the world during 
Yusim’s childhood in Moscow. 
Despite the difficulty of finding 
religious and spiritual texts in 
the Soviet Union, Yusim’s mother 
avidly pursued books on Judaism, 
Hare Krishna, and Buddhism, 
among others. Yusim’s grandfa-
ther, Yefim, asked his deceased 
wife to intercede when Yusim’s 
family was awaiting visas to 
immigrate to the United States in 
1981. The visas came two weeks 
later. At the age of 5, Yusim 
arrived in Chicago with her 
family. She took more after her 
physics professor father, however, 
who saw his Judaism as a cultural 
rather than a spiritual identity. 
The same scientific mindset car-
ried Yusim into her time at the 
Yale School of Medicine. 
“Science was the currency 
of knowledge and of exchange,” 
Yusim said. “What led me to 
pursue medicine was that I had 
always been so interested in 
the mind and how the mind 
works.” But then came residency. 
On paper, Yusim’s life looked 
mapped out, tidy, fulfilled: 
trudging valiantly through the 
most rigorous step of her medi-
cal education, in a relationship 
with a kind man, with a future 
in a field she loved. 
“Here I was, training to be a 
psychiatrist and to help people 
lift depression and anxiety from 
their lives,” Yusim said. “So why 
Digitized medical 
student theses have 
been downloaded tens 
of thousands of times 
by researchers around 
the world. Part of an 
ongoing project to 
bring as much human 
knowledge as possible 
online and advance 
scientific inquiry, it is 
run through the Medi-
cal Library with assis-
tance from the office 
of Alumni Affairs.






is interconnected with one 
another and to all living organ-
isms,” Yusim writes. 
“My hope is that people will 
get a sense of how to integrate 
more traditional medical train-
ing with the slightly less con-
ventional spiritual approach,” 
Yusim said. “They’re actually  
not incompatible—you can tap  
in and utilize many spiritual 
principles and ideas in the ser-
vice of healing.”
—Natasha Strydhorst
Anna Yusim, M.D. ’06, 
spent her childhood 
in secular Soviet 
Moscow. Her father, 
a physics professor, 
viewed his Judaism 
in cultural terms, and 
Yusim entered Yale 
School of Medicine 
similarly predisposed 
toward agnosti-
cism. Since that time, 
although studying 
and practicing in a 
scientific field, she has 
come to appreciate 
the importance of spir-
ituality in her own life, 
as well as its capacity 
to help others.
was I feeling kind of depressed 
and anxious myself? … I was 
ready for my spiritual education 
to begin.” 
While maintaining her natu-
ral skepticism and a physician’s 
analytic mindset, Yusim took 
her first tentative steps into 
where and how the “world of 
spirit interacts with the world 
of science.” She describes her 
decade-long quest to unite the 
two sides of human experience 
as a key component of her life’s 
purpose (alongside helping 
her patients and nurturing her 
marriage)—and the impetus for 
writing Fulfilled. Having found 
and defined that life purpose, 
Yusim set out, through her psy-
chiatric practice and the stories 
of herself and her patients, to 
help others—patients and read-
ers—do the same. 
“There’s no cookie-cutter  
approach,” Yusim said. 
Psychiatric and spiritual guid-
ance is a relationship, she said. 
“It’s really working with individ-
uals to help them connect to the 
soul in the most essential and 
real way to them.” Integrating 
medicine and spiritual prac-
tices like meditation has helped 
Yusim identify goals for finding a 
fulfilled life. “All of us face criti-
cal decision points where we can 
choose to be authentic or not … 
to align with our true selves or 
with who we think we have to 
be,” Yusim writes. “I know that 
I am not alone in having lived 
much of my life out of align-
ment with who I really am.” Her 
realization of this misalignment 
came early in her psychiatry 
residency. Yusim acknowledged 
the veneer of perfection she’d 
built around the emptiness she 
felt inside, and set her sights on 
abandoning that perfectionism 
to address that root emptiness. 
In Yusim’s experience, the 
point of connection between 
science and spirituality is every-
where. Literally. Spirituality 
sees the world as more com-
plicated and connected than 
people perceive with their 
senses—quantum physics says 
the same. “According to quan-
tum physics, at a level of reality 
that is invisible to the human 




















Recent advances in genetics 
research suggest that many adult 
diseases have origins that can be 
traced to childhood. If more data 
could be gathered from stud-
ies that include children, those 
relationships could be examined 
with greater certainty, Bogue said. 
“One of the next broad themes in 
pediatric research will be what 
we call research across the life 
span,” added Bogue, who has 
served as chief medical officer 
of Yale New Haven Children’s 
Hospital since 2014. 
Starting this year, the Yale 
Center for Clinical Investigation 
(YCCI) will roll out a pilot fund-
ing program on life span research. 
Researchers from across depart-
ments at Yale will be encouraged 
to gather preliminary data on 
collaborative projects and use 
the results to apply for larger NIH 
grants. Bogue imagines projects 
that push the edges of medicine. 
“You could have a geriatrician 
working with a geneticist to iden-
tify biomarkers in Alzheimer’s 
disease that can be found in 
childhood,” he says.
Just like his childhood hero, 
Sherlock Holmes, Bogue thrives 
on asking the right questions 
about patient care or a new scien-
tific study. He recalls making his 
career decision after shadowing a 
pediatrician as a high schooler in 
his hometown of Tampa, Florida. 
Bogue earned his medical degree 
at the University of Virginia in 
1985 and completed his pediatrics 
residency at Vanderbilt University. 
He then devoted time to his pas-
sion for developmental biology 
  Putting children first  
watch an interview  
with Cliff Bogue at  
ymm.yale.edu/bogue
research. After finishing a criti-
cal care fellowship at Yale, Bogue 
joined its faculty in 1993.
Since then, pediatric research 
has moved at warp speed, Bogue 
says, especially as genetic 
sequencing costs have settled to 
affordable levels. He expects it to 
continue apace. “Up to 30 percent 
of patients we see in the pediat-
ric intensive care unit are there 
because something in their body 
didn’t form correctly from birth. 
Most of the time it’s a genetic 
mutation,” Bogue said. 
He sat down with Yale 
Medicine Magazine to talk more 
about research across the life 
span, the single most important 
activity for young children, and 
the perils of too much screen time. 
ymm.yale.edu46
question and answer
A F T E R T H E GR E AT R E C E S S ION, researchers in pediatric health worried 
that their field might suffer a permanent loss of funding. That concern faded 
as U.S. research dollars increased in recent years, but Cliff Bogue, M.D., 
FW ’93,  chair of Yale School of Medicine’s pediatric department, believes 
even more money should be invested today in child health research. Before 
and since taking the department’s helm in August 2017, Bogue has trav-
eled to Washington, D.C., to advocate for more pediatric research funding 
and resources from lawmakers and the National Institutes of Health (NIH). 
For him, the calculus couldn’t be simpler. “Think of the results a treatment 
could have on a 5-year-old who lives to 95, versus an 80-year-old who lives 
15 more years,” Bogue says.
{ To nominate a subject for Q&A, contactYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu




Kathleen RavenWhat does research 
across the life span 
mean? We are finding 
that a surprising number 
of diseases have their 
origins very early in the 
life span and they may 
not manifest until years 
later. If we understand 
these and can identify 
them, then we can inter-
vene much earlier. For 
our YCCI pilot program, 
the idea is to get groups 
of people together and 
started on a project. We 
want to investigate the 
biological, environmental, 
social, and psychological 
aspects of disease—many 
of which have their ori-
gins in childhood and 
even prenatally.
What is the single most 
important thing a par-
ent can do for his or her 
child? I think we should 
worry about the increas-
ing amount of time chil-
dren spend watching a 
screen, whether it be TV 
or video games or iPads, 
and less time spent inter-
acting with others. This 
constant screen time can 
actually change the neu-
ral networks in the brain. 
One way to counteract 
this is through reading 
and actively playing. If 
there was a single greatest 
predictor of how someone 
will do in life, it is based 
on how much vocabulary 
they were exposed to 
early in life. So much 
evidence suggests the 
importance of reading to 
children at an early age. 
What is the most memo-
rable moment of your 
career? There are quite a 
few memorable moments. 
All of them include 
patient recovery. A year 
ago, I had visit from a for-
mer patient, a young man 
now in his 20s, who had 
had a severe head injury. 
We didn’t think he would 
do much except be in bed 
the rest of his life. But he 
pulled through and went 
through rehabilitation 
therapy. He came back 
to see me because he had 
just won a gold medal at 
the Paralympics in Brazil. 
What will be your prior-
ity as chair? Much of 
my focus will be what 
all chairs must focus 
on, which is being an 
international leader in 
research, education, 
clinical care, innova-
tion, and collaboration. 
Another thing that is 
important to me is that 
our department main-
tains an environment in 
which people feel valued 
and excited to be here. 
There’s been a lot of dis-
cussion in our medical 
school and at a lot of 
schools about physician 
burnout, about the cul-
ture, and if clinicians 
feel valued. I’ve always 
felt like this department 
has a personal touch, and 
that people are its greatest 
resource. I think that’s 
important to continue. 
It’s nice to remember 
what we are all about: 
our privilege to care for 
children and their fami-
lies. To make lives better. 
It’s something that most 



















   The Schmuck in My Office: 
How to Deal Effectively with  
   Difficult People at Work
   By Cathy Shufro
Move over, Birds of North 
America and World’s Top 
Restaurants. Make room  
for a new field guide—to 
obnoxious co-workers.  
The Schmuck in My Office: 
How to Deal Effectively with 
Difficult People at Work 
helps readers reduce fric-
tion with unruly colleagues 
by understanding the 
psychological and biological 
causes of their behavior. The 
authors, both psychiatrists, 
identify disruptive personal-
ity types and offer strategies 
for working with them.
Jody J. Foster, M.D., M.B.A. 
and Michelle Joy, M.D. ’12, use 
stories to illustrate the traits 
of 10 personality types that 
include the Narcissus, the 
Bean Counter, the Venus Fly 
Trap, the Distracted, and the 
Robotic. The Narcissus, for 
example, is someone (usually 
male) who expects others to 
cater to him, seeks attention, 
fishes for compliments, sulks, 
frames insults as jokes, and 
spreads rumors. Colleagues 
may find themselves treating 
a narcissist like a glass orna-
ment for fear of offending 
him. The book explores what 
underlies these behaviors, 
explaining that the arrogance 
and bluster are compensatory: 
“In his most private moments, 
the Narcissus fears that he 
isn’t all that great.” 
So how to endure the 
narcissist who wreaks 
havoc in the workplace? It 
helps if co-workers respond 
promptly to requests or invi-
tations, because narcissists 
are quick to feel snubbed. 
Managers can prevent them 
from hogging credit by 
rewarding teamwork more 
than solo efforts. And col-
leagues can help narcissists 
digest criticism by deliver-
ing it inside a “compliment 
sandwich” that begins and 
ends with praise. 
Readers will benefit from 
such strategizing, Joy noted 
in a recent interview. “If 
you’re having a hard time 
at work because of a dif-
ficult person, it can make a 
huge proportion of your life 
uncomfortable. But it’s not 
just about how happy we are 
at work. It’s also about the 
safety of our patients.” The 
Joint Commission issued a 
Sentinel Event Alert in 2008 
warning that workplace strife 
can lead to errors. Disruptive 
and intimidating behaviors 
may also hasten employee 
turnover and increase costs.
Joy met Foster, the prin-
cipal author, in 2013 when 
Foster was her attending 
on the acute psychosis unit 
at Pennsylvania Hospital in 
Philadelphia. Foster chairs the 
hospital psychiatry depart-
ment and serves as a clinical 
professor at the University 
of Pennsylvania’s Perelman 
School of Medicine. Joy now 
works at the Philadelphia VA 
Medical Center.
During the five years 
required to pitch, write, and 
edit the book, Joy said the 
partnership worked well 
because Foster has experience 
at the intersection of psy-
chiatry and institutional cul-
ture, and a master’s from the 
Wharton School, while Joy has 
a long-time interest in writing. 
Joy found time to write 
while at Yale School of Medi-
cine. Physician-author Randi 
Hutter Epstein, M.D. ’90, 
M.P.H., M.S., served as a men-
tor when Joy edited the Yale 
Journal of Humanities in 
Medicine. Joy also worked 
with the late gastroenter-
ologist and writer Howard 
M. Spiro, M.D., and partici-
pated in a writing group led 
by psychiatrist John Strauss, 
M.D. ’59, now professor emer-
itus of psychiatry.
Joy and Foster don’t 
intend the book to be a 
diagnostic tool, but rather a 
rough guide to what makes 
co-workers irritating. “No 
person is going to exactly fit 
into one category and not the 
other,” Joy said. “You can get 
a sense of what ballpark to 
go to: ‘OK, the Robotic fits, 
but maybe the Bean Counter 
kind of fits, too.’ Because 
often there’s an overlap.”
Foster and Joy counsel 
empathy (and sometimes 
therapy) for the irritating co-
worker. “They’re not setting 
out to be a difficult person,” 
said Joy. “They’re struggling 












































{Send notices of new books toYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
book review
OV E R 25 Y E A R S, through an annual auction, students in the health professions have supported New 
Haven nonprofits that address issues of hunger and homelessness. “They are taking a more holistic 
approach to the issue of not having access to food,” said second-year medical student David Dupee, 
one of the auction organizers, as he addressed the crowd at the auction in Café Med on Dec. 7. “They 
are providing access to health care providers, social workers, and other resources that really address 
the context in which social inequality occurs. All of these programs depend on us.”
This year, the 25th Annual Hunger and Homelessness Auction raised $13,000 that will be distrib-
uted to Y2Y New Haven, Jewish Family Services, and Integrated Refugee and Immigrant Services.
—John Curtis
 Auction raises $13,000  
for hunger and homelessness
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